Curriculum Vitae

Dr. Peter Hersey, FRACP, D.Phil.,

Senior Staff Specialist in Immunology & OncologyConjoint Professor in Oncology

CVPH 16/05/11

CURRICULUM VITAE

1. PERSONAL PARTICULARS

NAME: HERSEY, Peter

2. ACADEMIC QUALIFICATIONS

M.B.B.S. (Adelaide) 1966

Awarded 8 prizes for Distinction in Surgery, Medicine, Obstetrics and Gynaecology

FRACP (Fellowship of the Royal Australian College of Physicians) Adelaide. Awarded 1969

D.Phil. (Oxon) Thesis 1973 - "Immunological mechanisms in tumor rejection"

Registration number MPO 153597

3. CURRENT POSITIONS HELD

2011-Present Professor of Melanoma Biology, University of Sydney.

1984 - Present: Senior Staff Specialist in Immunology and Oncology,Calvary Mater Newcastle Hospital.

1984 - 2008: Consultant Immunologist, Sydney Melanoma Unit

2008- Present Consultant Immunologist , Melanoma Institute Australia

1985 - Present: Conjoint Professor of Oncology, University of Newcastle.

1988 - Present: Medical and Research Director, Newcastle Melanoma Unit.

2006 - Present: Member, International Melanoma Working Group.

2007 - Present: Member, Global Task Force on Melanoma.

2006 - Present: Member, Advisory Board for Melanoma Research Society.

2007 - Present: Member, Advisory Board for NSW Melanoma Network.

2007 - Present: Member, NSWOG for Melanoma.

OTHER POSITIONS CURRENTLY HELD Editorial Board Member for the journals:

2

Melanoma Research Cancer Immunology & Immunotherapy Pigment Cell & Melanoma Research

Journal Of Immunotherapy Oncology TimesAssociate Editor for Journal of Immunology

Editorial Review Panel for Cancer Research, International Journal of Cancer, Oncogene, Clinical Cancer Research, Journal of Investigative Dermatology and others.

Member of the following societies: Australian Society for Immunology American Association of Immunologists American Association for Cancer Research Clinical Oncology Society of Australia Medical Oncology Group Fellow Royal Australian College of Physicians The Society for Biological Therapy Member, Steering Committee for Society for Melanoma ResearchConsultancies and Medical Advisory Boards: Advisor to Genta at submission to FDA, ODAC Committee, April 2004. Member Steering committee for Pfizer Ticilimumab trial A3671008 Medical Advisory Board, Medarex/Bristol Myers, New York, December 2004. Medical Advisory Board, Med Immune, Washington, December 2004. Medical Advisory Board, Pfizer, New York, August 2004. Bristol-Myers Squibb Medical Advisory Committee Meeting, Bangkok, February 16th, 2006 MedImmune Melanoma Advisory Committee Meeting, New York, March 9th, 2006. Onyx PRISM Steering Committee Meeting, New York, March 9th, 2006. Onyx PRISM Steering Committee Meeting, Atlanta, June 1st, 2006. Onyx PRISM Steering Committee Meeting, New York, December 8th, 2006. Pfizer Correlative Science Meeting on Ticilimumab, Washington, April 2nd, 2006. Pfizer Correlative Science Meeting on Ticilimumab, Los Angeles, October 26th, 2006. Pfizer Correlative Science Meeting on Ticilimumab, New York, March 8th, 2007. Abraxane Medical Advisory Committee, Los Angeles, April 16th, 2007. Pfizer Correlative Science Meeting on Ticilimumab, Boston, May 14th, 2007. Glaxo Smith Kline Advisory Board Meeting, London, June 12th , 2007. Pfizer Medical Advisory Board, Barcelona, September 6th, 2007. Pfizer Steering Committee Meeting, New York, March 6th, 2008. Pfizer Advisory Board, New York, April 18th, 2008. Medical Advisory Board Meeting on Ipilimumab, Bristol Myers Squibb/Medarex, Paris, November 7th & 8th, 2008. Adjuvant Medical Advisory Board Meeting, Bristol Myers Squibb/Medarex, Miami, December 6th & 7th, 2008. Glaxo Smith Kline Advisory Board Meeting, Vienna, May 15th, 2009. Pfizer Steering Committee Meeting on Tremelimumab, Orlando, May 29th, 2009.

GSK Global Melanoma Development Board Meeting. Oct15-16th Paris, 2009 Roche BEAM Advisory Board Meeting, Berlin Nov 18th 2009 GSK DERMA Steering Committee, Berlin Nov 19th 2009

GSK DERMA Steering Committee Meeting, Chicago June 7th 2010 GSK Global Melanoma Development Board Meeting, New York, July1-2 2010. GSK Global Melanoma Development Board Meeting, Sydney, November 3rd, 2010. GSK DERMA Steering Committee, Sydney, November 3rd, 2010. Incyte Medical Advisory Board, Philadelphia, January 31st, 2011. MERCK Melanoma Scientific Engagement Board, Newark, February 24th, 2011.

4. PREVIOUS POSITIONS HELD

1966: Resident Medical Officer, Royal Adelaide Hospital.

3

1967: Temporary Lecturer, Department of Pathology,University of Adelaide.

1968: Registrar in Nuclear Medicine, Institute of Medical andVeterinary Science, Adelaide.

1969: Registrar in General Medicine, Royal Adelaide Hospital.

1970: Senior Medical Registrar, Royal Adelaide Hospital.

1971-3: Nuffield Dominions Trust Fellow, Nuffield Department of Clinical Medicine, Oxford, D.Phil. Thesis "Immunological Mechanisms in Tumour Rejection”.

1974-5: Senior Research Fellow, The University of Sydney, Department of Microbiology and Immunology. Studies carried out on human patients with melanoma and leukaemia.Honorary Clinical Assistant, Royal Prince Alfred Hospital.

1976-83: Senior Staff Specialist in Immunology, Kanematsu Memorial Institute,Sydney Hospital.

1992-2007: Member, WHO Committee on Melanoma.

OTHER POSITIONS PREVIOUSLY HELD

1978-83: Secretary, Staff Specialists' Association, Sydney Hospital.

1984-87: Member, NSW Oncology Advisory Committee.Member, Staff Advisory Committee, Mater Misericordiae Hospital.Chairman, Academic Oncology Advisory Committee, University of Newcastle.

1999 - 03: Chairman, Skin Cancer Group. Clinical Oncology Society of Australia.

2001 - 05: Member, Grant Review Panel, National Health & Medical Research Council.

1998-2005: Member, National Research Ranking Committee of State Cancer Councils.

2004: Advisor to Genta incorporated at USA FDA Oncology Development and Advisory

Committee (ODAC) April 2004

1998-2007: Cure Cancer Australia Research Advisory Board

2008-2010 Reviewer of NH&MRC project and Program Grants

TEACHING

1) PhD Students

PhD Student Year Awarded Field of Research and Publications

Quiyuan CHEN 1995 Tumor Immunology a(124,129,130,133)

Zhaoyi SI 1996 Tumor Immunology (127,128,140,147,151)

Kristen RADFORD 1997 Tumor Biology (142,148,153,158)

Ben CURRY 2000 Tumor Biology (145,159,170,171,177)

4

Pauline HANRAHAN 2000 Early Detection of Melanoma (141,154,160,184,193)

Wayne THOMAS 2001 Apoptosis of Melanoma (140,151,155,163,180,181,182,183)

Xu Dong ZHANG 2001 Apoptosis of Melanoma (168,174,176,179,180,181,182,183,186

Christian GRAY 2003 Tumor Immunology (168,176,180,185,186,189,199)

Nizar Mhaidat 2007 Overcoming Resistance of Human Melanoma to Chemotherapy-Induced Apoptosis (229,230,237,238,243)

Chen Chen JIANG 2008 ER Stress in Melanoma (233,235,249)

David Wroblewski In progress Targeting Adaptive Mechanisms to ER Stress in Melanoma

Andrew Weir In progress Role of C-Myc in ER Stress Response in Melanoma

Kwang Hang Tay In progress The Role of Gadd 153 in Melanoma

Hsin-Yi Tseng In Progress Overcoming resistance to Immunotherapy a Publications

2) Oncology Teaching

2005-2010. Basic Oncology Science course for Oncology registrars, NSW cancer Institute

Assisted in design of Oncology Course for Undergraduates. Continues teaching of 5th Year Students about management of melanoma. Education courses for general Practitioners in Hunter region

3) Internet Based Teaching

Management of melanoma . An internet course designed by Dr Scott Menzies and Professor McCarthy University of Sydney

5

PARTICIPATION IN CLINICAL TRIALS

(1) Principal Investigator -Immunotherapy of Stage IIb, III Melanoma with Vaccinia Melanoma Cell Lysates (VMCL) -1988-2000

Chairman of a randomised phase III study to evaluate the efficacy of a melanoma vaccine in patients with Stage IIb, III melanoma. The trial was run by the NH&MRC Trials Centre and accrued 700 patients. The results have been published in J. Clin. Oncology 20:4181-4190, 2002.

(2) Principal Investigator - Immunotherapy of Stage IV Patients with Melanoma Peptides -1998-2003

A number of melanoma peptides recognized by human T cells have been described. A phase I/II study to carry out immunotherapy with such peptides in centres in Newcastle, Sydney and Adelaide. Published in Cancer Immunology Immunotherapy. 54: 208-218, 2005

(3) Principal Investigator - Immunotherapy with Dendritic Cell (DC) Vaccines -1999-2007

Stage IV patients with DCs sensitized with their own tumor lysates or melanoma peptides. The study was partially funded by the NH&MRC. The first trial was published in Cancer Immunology Immunotherapy. 53:125-134, 2004.The second trial is published in Cancer Immunology Immunotherapy.57:1039-1051, 2008.

(4) Co-Investigator - PEG-Intron in Patients with Stage III Melanoma -2002-2006

Participation in the PEG-Intron Interferon Trial in patients with stage III melanoma, conducted by the EORTC (Trial 18991). Published in Lancet372 9633 117-127, 2008.

(5) Co-Investigator - ECOG 1697. 2004-ongoing

Participating in a trial comparing 4 weeks of high dose interferon with observation in patients with Stage II/III melanoma.

(6) Co-Investigator - Bcl-2 Antisense. Genta/Aventis. -2001-Completed

Participation in a randomised trial comparing DTIC alone with DTIC and Bcl-2 antisense in patients with Stage IV melanoma, sponsored by Genta Incorporated, California. 770 patients assured into the study . Results published in J Clin Oncology 24:4738-4745, 2006.

(7) Co-Investigator - Patrin 2/Orion -2002-2007

This is a randomised phase III study in patients with Stage IV melanoma comparing chemotherapy (Temozolomide) alone with chemotherapy plus an alkyl transferase inhibitor. The trial results to be published in JCO Watson et al 2008.

(8) Co-Investigator - Celgene/ICON – 2002-completed 2004.

Study of a new thalidomide derivative in patients with metastatic disease who have failed standard treatment. Manuscript submitted 2009

(9) Co-Investigator – Med Immune MI-CP095. – 2004-Completed 2005.

This trial tested the efficacy of a monoclonal antibody against the integrin αVβ3 on melanoma cells in treatment of patients with stage IV melanoma. Presented at ASCO 2005 Abstract 7507. Published Hersey et. al.2010 in Cancer. See publication number 259 below

(10) Vaccine Immunotherapy of stage 4 melanoma. Antigenics Heat Shock Protein Vaccine Trial – 2002-completed 2005. Published JCO 26:955-962 2008

6

(11) Co-Investigator – (Luitpold) Taxoprexin in Treatment of Stage IV Melanoma -2004-2007 A randomized trial comparing a new Paclitaxel drug with standard chemotherapy with DTIC.

ASCO Abstract 9056, 2008.

(12) Co-Investigator – Glaxo Smith Kline. Interleukin 18 in Treatment of Stage IV melanoma – 2005This is a phase II study of a new cytokine in treatment of melanoma. Completed.

(13) Principal Investigator and Co-Investigator –Treatment of Disseminated (Stage IV) Melanoma with IFN-2 and/or Chemotherapy

We were the first to initiate trials on the treatment of melanoma with recombinant alpha interferon (rIFN-) in Australia and initiated (with the Centre in Brisbane) Phase II studies on the combination of rIFN- and chemotherapy with DTIC. These studies led to a national randomized controlled trial of this treatment. Melanoma research 3:133-138 1993

This was followed by Phase II studies on the efficacy of INF-+5FU. Melanoma research 7:513-516, 1997.

(14) Co-Investigator –Phase I Study of Intratumoral Injection of GM-CSF in Treatment of Subcutaneous Melanoma.This study was conducted together with Dr. Coates in the Sydney Melanoma Unit and has resulted in a new appraisal of this cytokine for therapy of melanoma. Melanoma Research 6:247-255 1996.

(15) Co-Investigator – Genetronics Phase II Trial of Intralesional BCNU Given by Electroporation -1999-2000. Melanoma research 15:45-51 2005.

(16) Co-Investigator –Maxim Pharmaceuticals –Randomized Phase III Trial of DTIC versus DTIC + Histamine -2000-2004Cancer Immunology Immunotherapy 53:840-841, 2004.

(17) Co-Investigator – Phase II Trial of a Novel Antineoplastic Agent PNU-159548. -2000-2001

(18) Co-Investigator – Phase I Trial of Intralesional Coxsackie A21 Virus in Melanoma. 2003-Ongoing. Clin Canc Res, 10: 53-60, 2004.

(19) Co-Investigator – Randomized Trial of Sentinel Node Biopsy in Stage II, III Melanoma. MSLT-11 Commenced 8/2005. Ongoing.

(20) Co-Investigator – Phase III Randomized, Placebo Controlled Study of Sorafenib/ Nexavar in Repeated Cycles of 21 Days in Combination with Paclitaxel-Carboplatin Chemotherapy in Subjects with Unresectable Stage III or Stage IV Melanoma. Commenced 5/2005-completed 2007. Hauschild et al JCO 27:2823-2830, 2009.

(21) Co-Investigator – Randomized Double-Blind Multicentre Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine and Melanoma Vaccine Monotherapy in HLA-A *0201 – Positive Patients with Previously Treated Unresectable Stage II or IV Melanoma. Sponsor: Medarex Ltd. Commenced 9/2005.

(22) Co-Investigator – A Multicenter, Randomized, Double-blind, Study of Oral Bosentan in Patients with Stage IV Metastatic Melanoma. Sponsor: Aventis Ltd. Commenced 8/2005-Completed 10/2007. Presented at ESMO 2008

(23) Co- Investigator – A Phase I, Open-label Study of Extended Dosing with PatrinTM in Combination with Temozolomide in the Treatment of Patients with Advanced Melanoma. Completed

(24) Principal Investigator – A Phase I Study of Intralesional PV-10 Chemoablation in Subjects with Metastatic Melanoma. Commenced 9/2005. Melanoma Research, In press, 2008.

7

(25) Co-Investigator - Phase 2 Clinical Trial of 17-allylamino-17-demethoxy-geldanamycin (KOS-953) Tanespimycin in Metastatic Melanoma. Sponsor: Kosan Biosciences. Commenced May 2006. (ASCO Abstract 8558 2007)

(26) Co-Investigator – Phase 2, Open Label, Single Arm Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of CP-675,206 in Patients with Advanced Refractory and/or Relapsed Melanoma (A3671008). Sponsor: Pfizer. Commenced May 2006.Completed 4/07 (ASCO Abstract 9023 2008) Published Kirkwood et al Clin Canc res. 2010. See publication 261

(27) Co-Investigator – A Phase 3, Open Label, Randomized, Comparative Study of Ttremelimumab and Either Dacarbazine or Temozolomide in Patients with Advanced Melanoma (A3671009).Sponsor: Pfizer. Commenced May 2006.-completed 8/07 ASCO Abstract LBA 9011 2008

(28) Co-Investigator – A Phase II, Multi-centre, Open-Label, Parallel Group, Randomised Study to Assess the Safety and Efficacy of AZD6244 vs Temozolomide in Subjects with Unresectable AJCC Stage 3 or 4 Malignant Melanoma. Sponsor: AstraZeneca. Commenced June 2006.Completed 8/07 (ASCO Abstract 9033 2008)

(29) Co-Investigator – A Phase III Randomized, Double Blind, Multinational, Multicenter Study of Ipilimumab Therapy in Combination with Dacarbazine in Treating Patients with Unresectable, Stage IV or Recurrent Stage III Melanoma (CA184-024). Sponsor: Medarex/Bristol Myer Squibb.Commenced December 2007.

(30) Co-Investigator – A Randomized, Double-Blind, Multi-center, Phase II Fixed Dose Study of Multiple Doses of BMS-734016 (MDXl-010) Monotherapy in Patients with Previously Treated Unresectable Stage III or IV Melanoma (CA184-022). Sponsor: Medarex/Bristol Myer Squibb. Commenced January 2007.

(31) Co-Investigator – A Phase II Study of LY573636 as second line treatment of patients with unresectable metastatic melanoma. Sponsor: Eli Lilly. Commenced May 2007.

(32) Co-Investigator – A Randomized Phase III Clinical Trial of STA 4783 (Elesclomol) in Metastatic Melanoma. Sponsor: Synta Pharmaceuticals. Commenced February 2008. Stopped March 2009. (ASCO Abstract LBA9012 2009)

(33) Co-Investigator – A Randomized Trial of DTIC Plus or Minus Genasense in Treatment of Stage III Melanoma with low LDH levels.. Commenced March 2008. Accrued March 2009.

(34) Adjuvant Immunotherapy with Ipilimumab in high risk resected stage 111 melanoma. EORTC 18071 BMS CA184-029 Commenced January 2009.

(35) DERMA trial. Adjuvant immunotherapy with rMAGE-A3 +AS15 in resected stage 111 MAGE A3 positive patients GSK. Commenced January 2009.

(36) M10-440 .A Randomized,double blind ,placebo controlled ,Phase 2 study evaluating the efficacy of ABT-888 in combination with Temozolomide (TMZ) versus TMZ alone in subjects with Metastatic Melanoma. Commenced march 2009 Accrual complete March 2010

(37) Principal Investigator . Phase 1 study of proton pump inhibitors plus N-acetyl cysteine in treatment of patients with stage 4 melanoma. Approved August 2008. In progress.

(38) Piramal P276-00/27/28. Open label two stage phase 2 study of P276-00 in malignant melanoma positive for Cyclin D1 expression. Trident . submitted March 2009.

(39) Abraxane. An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients with Metastatic Malignant Melanoma. Submitted June 2009.Not commenced

8

(40) An Open-Label, Multi-Center Phase II Study of Continuous Oral Dosing of RO5185426 (PLX4032) in Previously Treated Patients with Metastatic Melanoma. Commenced October 2009.Accrual complete March 10 2010

(41) Roche Brim 3. randomised trial comparing NP22657/PLX4032 with DTIC in patients with Metastatic melanoma. Commenced March 2010

(42) GSK Phase 2 study of BRAF inhibitor GSK2118436 in previously treated patients with melanoma To commence in August 2010

TRANSLATIONAL RESEARCH ACHIEVEMENTS

Research achievements prior to 2004 1. Award of Nuffield Dominion Fellowship for PhD studies in Oxford. 2. One of the first to describe natural killer cells and to characterise effector cells in blood and lymph nodes against melanoma. Limited description of the melanoma antigens recognised by the immune system 3. First to study effects of ultraviolet irradiation on the immune system in humans4.. Identification of factors from melanoma inhibiting immune responses. First investigator to initiate large phase III studies of immunotherapy in patients with melanoma in Australia. 5.. We were the first to examine the role of TNF related apoptosis inducing ligand (TRAIL) against melanoma and expression of its receptors on melanoma lines and fresh isolates of melanoma. These studies remain a model for similar studies in other cancers. It remains a major area of research. 6.. We were the first to evaluate multimarker PCR assays to detect circulating melanoma cells in a large well planned prospective study. Our conclusions are still relevant today (i.e. false negative rate too high to make the test of practical utility). 7.. We were the first to identify older men (i.e. over age of 50) as the group most at risk from dying of melanoma and to carry out a series of well planned population studies on interventions that target this group. 8.. Studies on resistance of melanoma cells to apoptosis becomes a major focus of the laboratory.

Research achievements since 2004 1. Completion of 3 phase I/II trials of new immunotherapeutic approaches in treatment of patients with metastatic melanoma: (1) Use of modified high avidity melanoma peptide vaccines ; (2) Dendritic vaccine with autologous lysates or melanoma peptide ; (3) with or without interleukin-2 . Conclusions: (i) the clinical results seen did not justify the complexity of this therapeutic approach; and (ii) further work was needed to evaluate combinations with immunotherapy which may increase the sensitivity of melanoma to immunotherapy 2. Identification of resistance pathways against TRAIL-induced apoptosis in melanoma and therapeutic agents against them. We were the first to show that activation of the MEK/ERK pathway was a key factor in resistance to TRAIL (Oncogene 22:2869-2881, 2003 IF: 6.440 C: 49). Immunohistological studies on sections of melanoma showed that activation of the ERK pathway was related to progression of melanoma (). Moreover, the relative expression of protein kinase C epsilon in melanoma was a determinant of MEK/ERK activation Subsequent studies with inhibitors of MEK have shown their ability to induce apoptosis was due to upregulation of Bim and PUMA and down-regulation of Mcl-1.In addition to use of MEK inhibitors (or BRAF inhibitors) we were among the first to show that sensitivity to TRAIL could be increased by the use of histone deacetylase inhibitors . This was associated with upregulation of the pro-aoptotic Bim and down-regulation of Bcl-XL and Mcl-1

9

3. Discovery of agents that upregulate TRAIL death receptors on melanoma. Studies on melanoma cell lines (Clinical Cancer Research 7:966S-973S, 2001 IF: 6.250 C: 33) had shown that fresh isolates of melanoma frequently had low expression of receptors for TRAIL. These findings were supported by extensive immunohistology studies which showed decreased or undetectable levels of death receptors for TRAIL associated with progression of melanoma 4. Identification of mechanisms of action and resistance pathway against chemotherapy in melanoma. To better understand the basis of resistance of melanoma to chemotherapy we have investigated the mechanism of killing of commonly used chemotherapeutic agents against melanoma. In respect to the Taxols it was shown that activation of caspase 2 and the JNK pathway was involved Most importantly it was found that Taxols strongly activate the MEK/ERK pathway in some melanoma cells Studies on Dacarbazine or the oral form of the drug, Temozolomide (TMZ), indicated that apoptosis was not a major mechanism of action and that induction of senescence appeared to be the main outcome. This appeared to be p53 dependent and mediated by p21 These studies on TMZ led to a closer analysis of the role of p53 , which has since become one of the major themes in the laboratory. Eg publications 229.230,237,238,2395. Recognition of endoplasmic reticulum (ER) stress as a driver of malignancy and resistance to therapy in human melanoma. We are (PH 55) among the first groups to show that whereas normal cells may undergo cell death in the face of prolonged ER stress, melanoma cells have developed adaptive processes that account for progression of the disease and its resistance to therapy. Eg publications233,235,236,241,247,248,253255,257260,262.Translational research leading to phase 1 studies in melanoma patients with high LDH levels.Continues to be major focus of research6.Micro RNAs (miRNAs). . Given the importance of translation in control of Mcl-1 levels we have carried out screening of global miRNA expression profiles using a Ilumina Bead ArrayTM platform before and after exposure to the ER stress inducer Tunicamycin to identify miRNAs that may be involved in regulation of Mcl-1 protein levels. (Work in progress)

10

INVITED SPEAKER AT INTERNATIONAL MEETINGS

These are listed in chronological order below.

"The role of natural killer cells against tumours". In Symposium: "Effector mechanisms against tumours", Manchester, 1979.

"Cell mediated immunity in cancer patients". In Symposium: "Immunological evaluation of the cancer patients", 13th International Cancer Congress, Seattle, 1982.

Effects of ultraviolet irradiation on the immune system in man". Second World Congress on Skin Cancer, New York, March 1985. Skin Cancer Foundation, New York.

"Effects of recombinant leukocyte interferon (rIFN-A) on tumor growth and immune responses in patients with metastatic melanoma". In Symposium: "Developments in the treatment of malignant and viral disorders with recombinant interferon", 14th International Chemotherapy Congress, Osaka, Japan, June 1985.

"Current status and future prospects for immunotherapy of melanoma". In Symposium: "Update in Cellular and Tumor Immunology", Meeting of the Canadian Society for Clinical Investigation, Vancouver, B.C., September 1985.

"Recombinant interferon alpha (2A) combined with dacarbazine in treatment of metastatic melanoma." ISIR-TNO Meeting, Helsinki, 1986.

"Active immunotherapy with viral oncolysates". Invited as General Motors Visiting Professor to Symposium "Tumor specific antigens and active specific immunotherapy in man", University of South California, Cancer Center, Los Angeles, December 1988.

"T cell responses in patients with melanoma". One of only 20 Invited Participants, Arnand Hammer Symposium, Salk Research Clinic, La Jolla, California, USA, January 3-6th, 1989.

Invited as Co-Chairman to the 2nd International Meeting on Melanoma held in Venice, October 1989. Session chaired: "Active Specific Immunotherapy of Melanoma".

Invited Participant, UCLA Symposium Cellular Immunity and Cancer Immunotherapy, Park City, Utah, January 27th - February 2nd, 1990.

Invited Speaker, 1st International Symposium of Interferon Alpha Therapy, Athens, November 1-4th, 1990.

Invited Speaker, "Effects of UV-A on natural killer (NK) cell activity, antigen presenting cells (APC) and induction of suppressor cells". 19th Annual Meeting of the American Society for Photobiology, San Antonio, Texas, June 22-26th 1991.

Invited Speaker, "Advances in the biology and clinical management of melanoma", Houston, November 20-23rd, 1991.

"MHC restricted recognition of melanoma by cytotoxic T cells". Keystone Symposia, Taos, New Mexico, February 1-8th, 1992.

Invited Member, WHO Program Committee Meeting, Brno, Czechoslovakia, June 2-3rd, 1992.

11

INVITED SPEAKER AT INTERNATIONAL MEETINGS.......Continued.

Invited Speaker and Chairman, "Melanoma antigens recognized by T cells", International Consensus Conference on Human Melanoma Antigens, Lausanne, Switzerland, November 12-14th, 1992.

Invited Speaker, New York Academy of Science Sponsored Conference, Specific Immunotherapy of Cancer with Vaccines, Washington DC, "Viral oncolysates in treatment of melanoma", January 22-24, 1993.

Invited Speaker, Third International Conference on Melanoma, Venice, March 31-April 3, 1993.

WHO Programme Committee, Crete, May 30th - June 1st, 1993.

Invited Speaker, "Active immunotherapy following surgical removal of high risk melanoma. Present status and future prospects". Society for Biological Therapy, Nashville, Tennessee, November 10-14th, 1993.

Invited Speaker "Effects of solar radiation on the human immune system". UV Monitoring and Assessment Program Panel, Miami, Florida, March 1-4th, 1994.

Invited Speaker, "Immunobiology of melanoma progression" "Current status of melanoma vaccine trials in Australia". International Melanoma Conference, Brisbane, April 4-6th, 1994.

WHO Program Committee Meeting, Capri, Italy, June 1-3rd, 1994.

Johnson & Johnson Guest Speaker, "Effects of Ultraviolet Radiation (UVR) on the Human Immune System" Australian Society for Experimental Pathology Annual Scientific Meeting. September 26-29, 1994. Adelaide.

Invited Speaker, "The Influence of Different Cytokines on T cell Responses to Tumor Cells" Annual Meeting of the International Society for Interferon Research, October 2-7th, 1994. Budapest.

Invited Speaker, Keystone Symposia Immune Evasion. Taos, March 25th-30th, 1994.

Invited Speaker, Symposium "Molecular Advances in Melanoma Diagnosis and Treatment", Pittsburgh, February 21st, 1995.

Invited Participant, OECD Workshop on "Gene Delivery Systems", Ottawa, Canada, June 28-30th, 1995.

Invited Speaker, "Melanoma Vaccines in Therapy of Melanoma",Dermatology 2000, Vancouver, May 31st, 1996.

WHO Program Committee Meeting, Warsaw, Poland, June 6-8th, 1996.

Invited Speaker, National Cancer Institute Extramural Program Workshop on Tumor Vaccines. January, 1997.

Bruce Cain Memorial Lecturer, “Vaccines in Treatment of Melanoma”, New Zealand Society for Oncology, Palmerston, New Zealand, May 1st-2nd, 1997.

Invited Speaker, “Adjuvant Treatment of Melanoma, 4th World Conference on Melanoma, June, 1997.

12

INVITED SPEAKER AT INTERNATIONAL MEETINGS.......Continued.

Invited Speaker, “Adjuvant Treatment of Melanoma”, 19th World Congress of Dermatology, June, 1997.

Invited Speaker, “New Insights into Vaccine Treatment of Melanoma”, 1st International Symposium on Melanoma, Rome, June 18-20th, 1998.

Invited Speaker, “Vaccinia Melanoma Cell Lysates in Immunotherapy of Patients with Stage IIb and III Melanoma”, 3rd International Conference on The Adjuvant Therapy of Melanoma, London, March, 19-21st, 1999.

Guest Lecture, “TRAIL Induced Apoptosis of Melanoma”, 3rd International Conference on The Adjuvant Therapy of Melanoma, London, March, 19-21st, 1999.

Guest Lecture, “Clinical Relevance of Micrometastasis Detection”, International Symposium on Detection and Relevance of Micrometastases, Hamburg, Germany, September 17-18th, 1999.

Invited Speaker, “Regulation of TRAIL Induced Apoptosis of Melanoma”, Keystone Symposia, Santa Fe, January, 21-27, 2000.

Invited Speaker, Melanoma at the Millennium, Phoenix, Arizona, February 16-19th, 2000.

Invited Speaker, “Perspectives in Melanoma”, Pittsburgh, Pennsylvania, June 1st-3rd, 2000.

Invited Speaker, “Perspectives in Vaccine Treatment of Melanoma”, 5th World Conference on Melanoma, Venice, March 1st, 2001.

Invited Speaker, “Results of a Randomised Trial of Immunotherapy in Patients with Stage IIb and III Melanoma. 5th World Conference on Melanoma, Venice, March 1st, 2001.

Invited Speaker, ECOG Melanoma Group, Pittsburgh, June 10th, 2001.

Invited Participant, “Immune Monitoring of Cancer Patients”, Workshop sponsored by the Society for Biological Therapy. National Cancer Institute, USA, November 8th, 2001.

Invited Speaker, “Understanding resistance of melanoma to TRAIL induced apoptosis”, Fourth International Conference on Adjuvant Treatment of Melanoma. London, March 2002.

WHO Melanoma Programme Committee Meeting, Genoa, Italy, June 2002.

Invited Speaker and Co-Chairman, Society for Biological Therapy, November 7th-10th, 2002.

Invited Speaker, Biological Therapy of Melanoma Mediterranean Melanoma Meeting, May 2nd-5th, 2003.

Invited Speaker, National Cancer Institute “State of the Science Meeting – Turning Scientific Discoveries into Clinical Targets”. May 5th-8th, 2003.

Invited Speaker, First Annual Melanoma Research Congress. “Overcoming resistance of melanoma cells to apoptosis”. Philadelphia, June 21st-24th, 2003.

INVITED SPEAKER AT INTERNATIONAL MEETINGS.......Continued.

13

Earle A. Chiles Visiting Professor, Robert W. Franz Cancer Research Center, Providence Portland Medical Centre, Oregon Health and Science University. April 2nd, 2003.

Visiting Professor, Roswell Park Memorial Institute, Buffalo, New York. April 4th, 2003.

Invited Speaker, European Conference: Perspectives in melanoma management, Amsterdam, The Netherlands, October 10th-11th, 2003.

Invited Speaker, “Perspectives in Melanoma VI”, Miami, Florida, USA, November 13th-14th, 2003.

Invited Speaker, “5th International Conference on the Adjuvant Therapy of Malignant Melanoma”, Athens, Greece, March 18th-20th, 2004.

Invited Speaker, Keystone Symposia, “How melanoma cells evade TRAIL induced apoptosis”, March 25-30th, 2004.

Advisor to Genta for Oncology Development and Advisory Committee, Bethesda, Maryland, USA, April 2004.

Invited Speaker, “Evolution of melanoma as a model for biological therapy”. Society for Biological Therapy, San Francisco, November 2004.

Visiting Professor, Department of Medicine and Surgery, UCLA Medical Centre, Los Angeles, April 14th, 2005. – Presentation – “Does the immune system select for apoptotic resistance in melanoma cells?”

Invited Speaker, “A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-552, a humanized monoclonal antibody directed against the human alpha v beta 3 (avb3) integrin, + dacarbazine (DTIC) in patients with metastatic melanoma (MM)”. 41st

ASCO Annual Meeting, Orlando, Florida, USA, May 13-17, 2005.

Invited Speaker, “Allogeneic Vaccines in Treatment of Melanoma”, 6th World Congress of Melanoma, Vancouver, Canada, September 2005.

Invited Speaker, Keystone Symposia,”TRAIL Biology and Melanoma”, Sante Fe, USA, January 2006.

Invited Participant, Third International Symposium on Melanoma, New York, USA, March 10-11th, 2006.

Invited Participant, “International Melanoma Working Group”, Prague, November 6-7th, 2006.

Invited Speaker, “Induction of Death Receptors for TRAIL by ER Stress”, ASI, Auckland, New Zealand, December 3rd – 7th, 2006.

Invited Participant, “Global Melanoma Task Force”, Paris, February 4-5th, 2007.

Invited Participant, “International Melanoma Working Group”, Florence, May 7-8th, 2007.

Invited Participant, “Global Melanoma Task Force”, Reykjavik, July 9-10th, 2007.

INVITED SPEAKER AT INTERNATIONAL MEETINGS.......Continued.

14

Invited Speaker, “Melanoma vaccination with cell line derived antigens”, First World Meeting of Interdisciplinary Melanoma, Barcelona, September 5-8th, 2007.

Invited Participant, “International Melanoma Working Group”, Huntington Beach, California, October 4-6th, 2007.

Invited Speaker and Chairperson, “Apoptosis Induction and Immunotherapy”, Society for Biological Therapy of Cancer, November 1, 2007.

Invited Participant, “Global Melanoma Task Force”, Rome, December 10-11th, 2007.

Invited Speaker & Chairman, “Immunoregulation and Metastasis”, 6th Biennial International Sentinel Node Society, Sydney, February 18th – 20th, 2008.

Invited Speaker & Chairman, Advisory Committee on Adjuvant Treatment of Melanoma. Sponsored by Schering Plough, February 20th, 2008.

Invited Participant, “Global Melanoma Task Force”, Vienna, April 21st, 2008.

Invited Speaker & Chairman, “Targeting Histone Deacetylase and DNA Methylation”, International Conference on Adjuvant Treatment of Melanoma. Marseille, France, June 19th – 21st, 2008.

Invited Speaker, (1) “New Insights in Drug Resistance in Melanoma” and (2) “Targeting Apoptosis in Melanoma”, Perspectives in Melanoma XII, The Hague, Netherlands, October 2nd – 4th, 2008.

Invited Participant, Global Melanoma Task Force, Scheveringen, Netherlands, October 4th, 2008.

Invited Speaker and Chairman, “Metabolic Approaches to Treatment of Melanoma”, Second World Meeting on Melanoma Cancer Centers, Florida, USA, November 19th – 22nd, 2008.

Invited speaker and Chairman, Intralesional therapy for melanoma. 6th International Symposium on melanoma, New York, March 12-14th, 2009.

Invited Speaker and Chair, “Allogeneic Vaccines”. 7th world congress on melanoma . Vienna May 12-16th, 2009.

Invited Speaker, “Apoptosis Mediators”. 7th world congress on melanoma . Vienna May 12-16th, 2009.

Invited speaker. “Proapoptotic treatment approaches in metastatic melanoma” .Third world meeting of interdisciplinary melanoma skin cancer centres. Berlin Nov 19-21 2009

Invited Participant, “International Melanoma Working Group”, Lansdowne, Virginia, May 3rd – 4th, 2010.

Invited Participant, “Global Melanoma Task Force”, Seoul, May 12-13th, 2010.

Invited Speaker, “Induction of apoptosis in melanoma cells”, Queenstown Molecular Biology Meeting, Queenstown, New Zealand, September 2nd, 2010.

Invited Speaker, “Induction of apoptosis by selective BRAF inhibitors: The key to therapeutic success?”, Society for Melanoma Research, Sydney, November 4-7th, 2010

15

INVITED SPEAKER AT INTERNATIONAL MEETINGS.......Continued.

Invited Speaker, “Advances in melanoma diagnosis and targeted therapy”, Melanoma Centres Meeting, Sydney, November 4-7th, 2010.

Invited Chairperson, “Adjuvant therapy of melanoma – What lies ahead”, Melanoma Centres Meeting, Sydney, November 4-7th, 2010.

Invited Participant, International Melanoma Working Group (IMWG), Naples, December 3rd-5th, 2010.

Invited Participant, Global Melanoma Task Force, Paris, June 21st-22nd, 2010.

Invited Participant, Global Melanoma Task Force, December 7th-9th, 2010.

Invited Speaker, “Where next in immunotherapy of melanoma”, Cancer Symposium, Wellington, New Zealand, February 15-16th, 2011.

Invited Participant, “HDAC Inhibitors for treatment of BRAF inhibitor resistance”, International Melanoma Working Group, Barcelona, Spain, April 10-12th, 2011.

Invited Speaker, “Targeted therapy in melanoma. Present and future”, European Association of Dermato-Oncology, Nantes, France, June 20th-23rd, 2011.

Invited Speaker, Global Conference on Developing New Treatment for Melanoma, Munich, Germany, July 7-8th, 2011.

INVITED SPEAKER AT NATIONAL MEETINGS

Invited Speaker, "Active immunotherapy following surgical removal of high risk melanoma. Present status and future prospects". COSA 20th Annual Scientific Meeting, Perth, Western Australia, November 24-26th, 1993.

Invited Speaker, Tumor Immunology Workshop, Perth, WA, October 24-26th, 1995.

Invited Speaker, Gene Therapy Symposium, ASCEPT Annual Meeting, Adelaide, December 5th, 1995.

Invited Speaker, “Regulation of TRAIL Induced Apoptosis of Melanoma”, Third Peter Mac Symposium, Melbourne, November 7-9th, 1999.

Invited Speaker, “Melanoma Cells in the Circulation”, Australasian College of Dermatologists, May 23rd, 2000.

Gordon Ada Lecture “Immunology of Melanoma”, Australian Society of Immunology, December 13-15th, 2000.

Invited Speaker, “Adjuvant Treatment of Melanoma”, Surgical Oncology Group of the Royal Australian College of Surgeons, Canberra, May 8th, 2001.

INVITED SPEAKER AT NATIONAL MEETINGS….. Continued

16

Invited Speaker, “Sensitisation of melanoma to apoptosis”, Inaugural Meeting of Australian Dermatology Research Association, Sydney, May 15th 2004.

Hunter Area Pathology Service, “Sensitization of Melanoma to Apoptosis”, April 6th, 2005,

Canbio Meeting, Adelaide, S.A. “Selection of Melanoma Cells by the Immune System for Resistance to Apoptosis”, September 26th, 2005,

COSA, Brisbane. “A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha v beta 3 (avb3) integrin, - dacarbazine (DTIC) in patients with metastatic melanoma (MM).” November 17th, 2005,

COSA, Brisbane. “Present status of immunotherapy for metastatic melanoma.” November 18th, 2005.

Newcastle HMRI Conference on Translational Cancer Research. “How Effective will TRAIL be in Treatment of Melanoma?” September 20th – 22nd, 2006.

MMRI Dendritic Cell Symposium. “Current Status of DC Vaccine Trials in the Sydney Melanoma Unit.” Brisbane, June 22nd, 2007.

COSA, Adelaide. “New treatments for metastatic melanoma”, November 15th, 2007.

COSA, Adelaide. “ER stress and LDH in melanoma. Part of the same spectrum”. November 15th, 2007.

Chairperson, “Immunotherapy Symposium”. MOGA 30th Anniversary Meeting, Canberra, ACT, August 12th, 2009.

Invited Speaker, “BRAF Inhibitors and New Melanoma Treatments”, North Coast Cancer Conference, Ballina, NSW, March 20th, 2010.

Invited Chairperson, “The immune system and cancer”, Medical Oncology Group Australia, Sydney, NSW, August 12th, 2010.

POSTER PRESENTATIONS AT INTERNATIONAL CONFERENCES

January 26-30th, 2005, Regulation of Cell Death in Oncogenesis, Hawaii. Presentation – “Cross resistance of melanoma to apoptosis induced by TRAIL and chemotherapy”.

April 16-20th, 2005. AACR, Anaheim, California. Poster – “Understanding resistance of melanoma to apoptosis”.

April 1-5th, 2006. AACR, Washington. Poster – “Melanoma cells resistant to TRAIL are more vulnerable to necrotic death induced by Cisplatin.

POSTER PRESENTATIONS AT INTERNATIONAL CONFERENCES……. Continued

June 2-6th, 2006. ASCO, Atlanta.

17

September 14-16th, 2006. Perspectives in Melanoma, Noordwijk, Netherlands. Poster – “Rose Bengal induces dual modes of cell death and has clinical activity against melanoma”.

October 26-29th, 2006. Society for Biological Therapy, Los Angeles. Poster – “Hurdles to overcome in treatment of melanoma by TRAIL”

November 8-11th, 2006. 18th EORTC–NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Prague.

December 3rd-6th, 2006. ASI, Auckland, New Zealand. Presentation – “Induction of death receptors for TRAIL by ER Stress”.

January 21st-27th, 2007. Keystone Symposium “Host Cell Interactions and Response to the Cancer Cell”, Keystone, Colorado, USA. Poster – “Induction of death receptors for TRAIL by agents which induce the ER stress response”.

April 15-17th, 2007. AACR, Los Angeles.

June 1st-5th, 2007. ASCO, Chicago. Co-Author – “Randomized Phase III Study of Paclitaxel and Carboplatin With or Without Sorafenib as Second Line Treatment of Patients with Metastatic Melanoma”.

May 30th – June 3rd, 2008. 44th Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago. Kirkwood, J.M., Lorigan, P., Hersey, P., et al. “A phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Poster Presentation.

February 1-4 2010. AACR Cell death mechanisms and Cancer Therapy. San Diego

“Induction of apoptosis in human melanoma. The key to therapeutic success?”, ASCO, Chicago, IL, June 4-8th, 2010.

June 3rd-7th, 2011. ASCO. “Targeting histone deacetylase to overcome resistance of BRAFV600E melanoma cells to apoptosis”.

June 3rd-7th, 2011. ASCO. “BRIM-2: An open-label, multicenter phase II study of RG7204 (PLX4032) in previously treated patients with <I>BRAF</I> V600E mutation-positive metastatic melanoma”.

June 3rd-7th, 2011. ASCO. “Morphologic and immunohistochemical (IHC) changes in metastatic melanoma (MM) tissue and associations with clinical outcome in patients (pts) & nbsp; on BRAF inhibitors (BRAFi).”

18

EXTERNALLY FUNDED RESEARCH GRANTS FUNDS FOR

TITLE INVESTIGATORS PERIOD EACH YEAR SOURCE

The role of melanoma Dr. P. Hersey 1977 $12,061 N.H. & M.R.C.antigens in human tumor A/Prof. W. McCarthyhost relationships

The role of melanoma Dr. P. Hersey 1978-80 $28,000 N.H. & M.R.C.antigens in human tumor A/Prof. W. McCarthyhost relationships

Immunological Dr. P. Hersey 1978-1980 $15,000 N.H. & M.R.C.reactivity to acutemyeloid leukaemiaantigens in man

Effects of UV Dr. P. Hersey 1982 only $18,752 N.H. & M.R.C.irradiation on theimmune system

Immunological Dr. P. Hersey 1977-78 $14,000 N.S.W. Statereactivity of human Cancer Councilsubjects with acuteleukaemia

Immunology in the Dr. P. Hersey 1976-77 $17,000 N.S.W. Statediagnosis and Cancer Counciltreatment of melanoma

Immunological aspects Dr. P. Hersey 1976-77 $29,000 Univ. Sydneyof melanoma Cancer Res. Fund

Investigation of Dr. P. Hersey 1978-79 $14,000 N.S.W. Statehypogammaglobulinaemia Dr. F. Gunz Cancer Councilin patients with C.L.L.

Investigation of Dr. P. Hersey 1978-79 $17,000 Clive and Veratumor escape Ramaciottimechanisms Foundation

Immunological studies Dr. P. Hersey 1979 $16,000 Univ. Sydneyin melanoma patients A/Prof. W. McCarthy Cancer Res. Fund

The role of suppressor Dr. P. Hersey 1980-81 $14,000 N.S.W. Stateactivity against A/Prof. W. McCarthy Cancer Councilimmune responses inthe pathogenesis ofmalignant melanoma

Investigation of Dr. P. Hersey 1980-82 $17,000 Tobacco Researchhypogammaglobulinaemia Foundationin cigarette smokers

19

FUNDS FOR TITLE INVESTIGATORS PERIOD EACH YEAR SOURCE

Investigation of the Dr. P. Hersey 1982-83 $ 20,000 N.S.W. Staterole of interleukins A/Prof. W. McCarthy Cancer Councilin the treatment ofmalignancies

Diagnostic applications Dr. P. Hersey 1978 $255,000 National Cancerof antibodies to human A/Prof. W. McCarthy to (mean $51,000) Institute (USA)tumour associated Prof. G. Milton 1982 (per year ) Contractantigens

The role of melanoma Dr. P. Hersey 1983 $ 35,000 N.H. & M.R.C.antigens in humantumor hostrelationships

Analysis of Interleukin Dr. P. Hersey 1983-85 $ 25,000 N.H. & M.R.C.2 induced cytotoxicityagainst human tumours

Investigation of the Dr. P. Hersey 1983 $ 17,000 Sydney Hospitalrole of interleukin Foundation forin the treatment of Researchmalignancies

Effects of ultraviolet Dr. P. Hersey 1985-86 $ 30,000 N.S.W. Stateirradiation on the Dr. F. Wilkinson Cancer Councilimmune system in man

Evaluation of Dr. P. Hersey 1985-87 $ 19,000 Hunter Valleymonoclonal antibodies Cancer Appealin the histologicalassessment of prognosisin melanoma

Clonal analysis of Dr. P. Hersey 1986-88 $ 51,000 N.H. & M.R.C.Interleukin 2 dependentT cells in melanomapatients

Monoclonal antibodies Dr. P. Hersey 1987-89 $ 29,000 N.H. & M.R.C.in the in vivo diagnosisof human melanoma

Immunotherapy with Dr. P. Hersey 1988-92 $ 35,000 N.S.W. Statevaccinia melanoma cell A/Prof. W. McCarthy Cancer Councillysates for treatmentof patients with badprognosis melanoma

20

FUNDS FOR TITLE INVESTIGATORS PERIOD EACH YEAR SOURCE

Analysis of melanoma Clin Prof P Hersey 1989-91 $ 74,000 N.H. & M.R.C.antigens recognized byhuman T cells

Ultraviolet radiation Clin Prof P Hersey 1990-93 $ 38,000 N.H. & M.R.C.in the induction ofsuppressor cells inmelanoma

Investigation of the Clin Prof P Hersey 1992 $ 18,680 Clive & Verafunction of a marker Ramaciottiof tumor progression Foundationin melanoma

Analysis of structures Clin Prof P Hersey 1993-95 $ 75,000 N.H. & M.R.C.involved in recognitionof human melanoma byT cells

Detection of melanoma Clin Prof P Hersey 1994-95 $ 43,000 N.S.W. Statecells in the circulation Cancer Council

Analysis of melanoma Clin Prof P Hersey 1994 $ 25,000 Clive & Veraantigens recognized Ramaciottiby T cells Foundation

Vaccinia melanoma cell Clin Prof P Hersey 1993-97 $ 18,000 Sydney Melanomalysates in treatment Prof. W.H. McCarthy Foundationof melanoma

Characterization of Clin Prof P Hersey 1993-95 $ 50,000 NBN Telethoninhibitors/cytokinesfrom melanoma cells

Detection of melanoma Clin Prof P Hersey 1996-97 $ 45,000 NSW Statecells in the circulation Cancer Council

Detection of melanoma Clin Prof P Hersey 1996 $ 16,100 Kilkearycells in the circulation Foundation

Detection of melanoma Clin Prof P Hersey 1996-97 $ 40,000 JP Morgan Fundcells in the circulation

Analysis of immune Clin Prof P Hersey 1997 $ 36,000 Kilkearyresponses to human Foundationmelanoma

Analysis of immune Clin Prof P Hersey 1997-99 $ 110,000 N.H. & M.R.C.responses to humanmelanoma

21

FUNDS FOR TITLE INVESTIGATORS PERIOD EACH YEAR SOURCE

Immunotherapy of melanoma Clin. Prof. P. Hersey 1998 $ 53,729.41 NH&MRCwith dendritic cells Dr. S. Menzies 1999 $ 55,198.98

Dr. G. M. Halliday 2000 $ 56,665.41

Assessment of photography Clin. Prof. P. Hersey 1998 $ 62,225.65 NH&MRCas an aid to early detection Dr. S. Menzies 1999 $ 26,280.39of melanoma in older males by Dr. C. A. D’Estegeneral practitioners Dr. A. Plummer

Infrastructure grant for Clin. Prof P. Hersey 1998-2000 $ 60,000 Melanoma and Skin melanoma research Cancer Institute

(MASCRI)

TRAIL induced apoptosis Dr. P. Hersey 1999-2001 $ 55,000 NSW SCCof melanoma Dr. A. Franco

TRAIL receptor expression Dr. P. Hersey 1999 $ 10,000 Margaret Mitchellon human melanoma

Treatment of melanoma with Dr. P. Hersey 1999 $ 18,120 Cecilia KilkearyTRAIL in combination withchemotherapy

Sensitization of melanoma to Dr. P. Hersey 2000 $ 10,000 Margaret MitchellTRAIL induced apoptosis

TRAIL receptor expression Dr. P. Hersey 2000 $ 15,000 Clive & Veraon melanoma in vivo Ramaciotti

Foundation

Immunotherapy of melanoma Dr. P. Hersey 2002 $165,000 NH&MRCwith dendritic cell vaccines Dr. G. Halliday 2003 $165,000

Dr. S. Menzies 2004 $165,000

The role of regulatory T cells Dr. P. Hersey 2002 $55,000 Leo & Jennyin patients with melanoma Leukaemia and

Cancer Foundation

Sensitization of melanoma to Dr. P. Hersey 2003 $136,000 NSW SCCTRAIL induced apoptosis Dr. X. D. Zhang 2004 $136,000

2005 $136,000

Regulation of TRAIL Dr. X. D. Zhang 2003 $ 17,000 HMRIreceptor expression in Dr. P. Herseymelanoma cells

Adjuvant immunotherapy Dr. P. Hersey 2004-2005 $50,000 RACPof melanoma with Australia Postvaccinia melanoma Medicalcell lysates Research Fund

22

FUNDS FOR TITLE INVESTIGATORS PERIOD EACH YEAR SOURCE

Overcoming resistance Prof. P. Hersey 2005 $164,250 NHMRCof human melanoma to Dr. X.D. Zhang 2006 $164,250chemotherapy Dr. J. Allen 2007 $164,250

Induction of apoptosis in Prof. P. Hersey 2005 $10,000 Margaret MitchellMelanoma by Docetaxel Dr. X. D. Zhang Research Fund

Effect of irradiation on Prof. P. Hersey 2005 $10,000 “Wig Week”TRAIL-R expression Research Fund

Molecular determinants Prof. R. Kefford 2006-2010 $7,895,340 NH&MRCof risk, progression and Prof. P. Hersey over 5years Program Granttreatment response in melanoma Prof. J. Thompson

A/Prof. G. MannDr. R. Scolyer

Molecular genetics of Dr. G. Mann 2006-2010 $750,000/year Cancer Institute,Melanoma predisposition Prof. J. Thompson for 5 years NSW

Prof. R. KeffordDr. S. MenziesDr. R. ScolyerProf. P. HerseyProf. R. Christopherson

Trials Co-Ordinator Prof. P. Hersey 2006-2009 $55,000 per Cancer Institute,Annum NSW

Infrastructure Grant for Prof. P. Hersey 2006 $220,000 Cancer Institute,Flow Cytometer NSW

Overcoming resistance of Dr. X. D. Zhang 2006-2009 $195,000/year Cancer Institute,Melanoma to apoptosis Prof. P. Hersey NSW

Cameron Research Fellowship Prof. R. Kefford 2006-2009 $166,000/year PrivateProf. P. Hersey Endowment

Equipment 2005 $31,000 University of2006 $22,000 Newcastle

RIBG

Characterization of p53 Dr. X.D. Zhang 2007 $75,000 Cure Cancerisoforms in human melanoma: Dr. K.A. Kiejda Australiado they play a role in Prof. P. Hersey Foundationchemoresistance?

The role of p53 isoforms in Dr. X.D. Zhang 2007 $10,000 Newcastle Materchemoresistance of human Dr. K.A. Kiejda MisericordiaeMelanoma Prof. P. Hersey Hospital

(Margaret Mitchell Grant)

FUNDS FOR

23

TITLE INVESTIGATORS PERIOD EACH YEAR SOURCE

The role of p53 isoforms in Dr. X.D. Zhang 2007 $20,000 Hunter Medicalchemoresistance of human Dr. K.A. Kiejda Research Institutemelanoma Prof. P. Hersey

Roles of the endoplasmic Dr. X.D. Zhang 2009-2011 $300,000 State Cancerreticulum and lysosome in Prof. P. Hersey over 3 yrs Council NSWTRAIL-mediated killing of Dr. R.F. Thorne Project Grantmelanoma

Targeting p53 isoforms, Dr. K.A. Kiejda 2009 $75,000 Cure Cancerdelta-40p53 and p53-beta, Dr. X.D. Zhang Australiato promote chemo-sensitivity Prof. P. Hersey Foundationin human melanoma

The microRNA signature of Dr. X.D.Zhang 2009 $10,000 Margaret Mitchellendoplasmic reticulum stress Dr. K.A. Kiejda Grantin human melanoma Prof. P. Hersey

Targeting p53 isoforms, Dr. K.A. Kiejda 2009 $30,000 Wig WeekD40p53 and p53β, to promote Dr. X.D. Zhang Project Grantchemo-sensitivity in human Prof. P. Herseymelanoma

Overcoming adaptation to Dr. X.D. Zhang 2009-2011 $491,250 NHMRCendoplasmic reticulum stress Prof. P. Hersey over 3 yrs Project Grantto sensitize melanoma to Dr. R.F. Thornechemotherapy

Molecular determinants of Prof. Kefford 2011-2014 12.05Million NHMRC Programrisk , progression and Prof. J. Thompson over 5 years Granttreatment response in Prof. P. Herseymelanoma Prof. G. Mann

Prof. R. ScolyerDr. N. Haywood

Targeting pro-survival Dr. X.D. Zhang 2010 $ 48000 Research Innovationmechanisms to sensitise Prof. P. Hersey Grant, NSW Cancermelanoma to immunotherapy Institute

The role of micro RNA-149 Dr. C.C. Jiang 2010 $ 90,000 Cure Cancer In regulation of Mcl-1 in ER Dr. X.D. Zhang AustraliaStress Prof. P. Hersey

Transcriptional regulation of Prof. P. Hersey 2010-2011 $144,300 NHMRC Mcl-1 during ER stress in Dr. X.D. Zhang China AusMelanoma Dr. L. Dong Exchange

Targeting p53 isoforms to Dr. X.D. Zhang 2009-2011 $272,000 NSW StatePromote chemosensitivity Dr. P. Hersey Cancer CouncilIn human melanoma

24

FUNDS FOR TITLE INVESTIGATORS PERIOD EACH YEAR SOURCE

Melanoma Institute Australia Prof. G. Mann 2010 $373,650 Cancer InstituteTranslational Research Program Prof. J. Thompson 2011 $747,300 NSW

Prof. R. Kefford 2012 $747,300 10/TPG/1-02Prof. R. Scolyer 2013 $747,300 Program GrantProf. P. Hersey 2014 $747,300Prof. S. MenziesDr. A. SpillaneDr. H. RizosDr. X. D. Zhang Prof. R. Christopherson

SUMMARY OF PUBLICATION DETAILS

- Total peer reviewed original papers = 273- Peer reviewed articles since 2006 = 53- Total career citations = 8,383- Average citations per publication = 25.79- Number of articles with > 100 citations = 16- Citations since 2006 = 2,521- Invited Book Chapters since 2007 = 4- H factor = 53

25

BIBLIOGRAPHY

1. Dong, L., Jiang, C.C., Thorne, R.F., Croft, A., Yang, F., Liu, H., de Bock, C.E., Hersey, P., and Zhang X.D. (2011) Ets-1 mediates up-regulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress. Oncogene (Accepted for publication).

2. Jiang, C.C., Lai, F., Thorne, R.F., Yang, F., Liu, H., Hersey, P., and Zhang X.D. (2011) MEK-Independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clinical Cancer Research 17:721-730.

3. Tseng, H.-Y., Jiang, C.C., Croft, A., Tay, K.H., Thorne, R.F., Yang, F., Liu, H., Hersey, P., and Zhang, X.D. (2010) Contracting effects of Nutlin-3 on TRAIL- and Docetaxel-Induced apoptosis due to up-regulation of TRAIL-R2 and Mcl-1 in human melanoma cells. Mol. Cancer Therapeutics 9(12):3363-3374.

4. Fonsatti, E., Maio, M., Altomonte, M., and Hersey, P. (2010) Biology and clinical applications of CD40 in cancer treatment. Seminars in Oncology 37(5):517-523.

5. Jiang, C.C., Lai, F., Tay, K.H., Croft, A., Rizos, H., Becker, T.M., Yang, F., Liu, H, Thorne, R.F., Hersey, P., and Zhang, X.D. (2010) Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of BimS. Cell Death Dis 1, e69;doi:10.1038/cddis.2010.48

6. Bowden, N.A., Ashton, K.A., Avery-Kiejda, K., Zhang, X.D., Hersey, P., and Scott, R.J. (2010) Nucleotide excision repair gene expression after Cisplatin treatment in melanoma. Cancer Research 70(20):7918-7926.

7. Mao, Z.G., Jiang, C.C., Yang, F., Thorne, R.F., Hersey, P., and Zhang, X.D. (2010) TRAIL-induced apoptosis of human melanoma cells involves activation of caspase-4. Apoptosis 15(10):1211-1222.

8. Yang, F., Tay, K.H., Dong, L., Thorne, R.F., Jiang, C.C., Yang, E., Tseng, H.-Y., Liu, H., Christopherson, R., Hersey, P., and Zhang, X.D. (2010) Cystatin B inhibition of TRAIL-induced apoptosis is associated with protection of FLIP(L) from degradation by the E3 ligase Itch in human melanoma cells. Cell Death & Differentiation 17:1354-1367.

9. Hersey, P. (2010) Immunotherapy of melanoma. Asia-Pacific Journal of Clinical Oncology 6(Suppl. 1):A2-A8.

10. Kefford, R.F., Clingan, P.R., Brady, B., Ballmer, A., Morganti, A., and Hersey, P. (2010) A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy.being treated with dacarbazine. Molecular Cancer 9:69.

11. Eisen, T., Shalimov, S., Trefzer, U., Hamilton, A., Hersey, P., Knight, R.D., Jungnelius, J.U., and Glaspy, J. (2010) Results of a multicenter, randomized, double-blind phase II/III study of lenalidomide in the treatment of pre-treated relapsed or refractory metastatic malignant melanoma. Cancer 116(1):146-154.

12. Kirkwood, J.M., Lorigan, P., Hersey, P., Hauschild, A., Robert, C., McDermott, D., Marshall, M.A., Gomez-Navarro, J., Liang, J.Q., and Bulanhagui, C.A (2010). Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clinical Cancer Research 16(3):1042-1048. (IF: 17.157)

26

13. Liu, H., Jiang, C.C., Lavis, C.J., Croft, A., Dong, L., Tseng, H-Y., Yang, F., Tay, K.H., Hersey, P., and Zhang, X.D. (2009) 2-Deoxy-D-Glucose enhances TRAIL-induced apoptosis in human melanoma cells through XBP-1-mediated up-regulation of TRAIL-R2. Molecular Cancer 8:122.

14. Zhuang, L., Scolyer, R.A., McCarthy, S.W., Murali, R., Zhang, X.D., Thompson, J.F., and Hersey, P. (2009) Lactate dehydrogenase 5 (LDH-5) expression increases with progression in melanoma and is associated with Bcl-XL and Mcl-1 but not Bcl-2 expression. Modern Pathology 23:45-53. (IF: 4.678)

15. Hersey, P., Sosman, J., O’Day, S., Richards, J., Bedikian, A., Gonzalez, R., Sharfman, W., Weber, R., Logan, T., Buzoianu, M., Hammershaimb, L., and Kirkwood, J.M. for the Etaracizumab Melanoma Study Group. (2009) A randomized phase 2 study of Etaracizumab, a monoclonal antibody against integrin αV β3, + Dacarbazine in patients with stage IV metastatic melanoma. Cancer 116:1526-1534. (IF: 5.238)

16. Beusterien, K.M., Szabo, S.M., Kotapati, S., Mukherjee, J., Hoos, A., Hersey, P., Middleton, M.R., and Levy, A.R. (2009) Societal preference values for advanced melanoma health states in the United Kingdom and Australia. British Journal of Cancer 101:387-389 (IF: 4.846)

17. Jiang, C.C., Wroblewski, D., Yang, F., Hersey, P., and Zhang, X.D. (2009) Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic Obatoclax Neoplasia 11(9):945-955. (IF: 5.191)

18. Zhuang, L., Scolyer, R.A., Lee, C.S., McCarthy, S.W., Cooper, W.A., Zhang, X.D., Thompson, J.F., and Hersey, P. (2009) Expression of glucose-regulated stress protein GRP78 is related to progression of melanoma. Histopathology. 54(4):462-470. (IF: 4.131)

19. Jiang, C.C., Yang, F., Thorne, R.F., Zhu, B., Hersey, P., and Zhang, X.D. (2009) Human melanoma cells under endoplasmic reticulum stress acquire resistance to microtubule-targeting drugs via XBP-1-mediated activation of Akt. Neoplasia. 11(5):436-447. (IF: 5.191)

20. Zhang, L. J., Chen, S., Wu, P., Hu, C. S., Thorne, R. F., Luo, C. M., Hersey, P., and Zhang, X.D. (2009) Inhibition of MEK blocks GRP78 up-regulation and enhances apoptosis induced by ER stress in gastric cancer cells. Cancer Letters 274 :40-46. (IF: 3.398)

21. Jiang, C.C., Mao, Z.G., Avery-Kiejda, K.A., Wade, M., Hersey, P., and Zhang, X.D. (2009) Glucose-regulated protein 78 antagonizes cisplatin and Adriamycin in human melanoma cells. Carcinogenesis 30:197-204. (IF: 5.406)

22. Watson, A.J., Middleton, M.R., McGown, G., Thorncroft, M., Ranson, M., Hersey, P., McArthur, G., Davis, I.D., Thomson, D., Beith, J., Haydon, A., Kefford, R., Mortimer, P., Baka, S., Sabharwal, A., Hayward, O., and Margison, G.P. (2009). O6-methylguanine-DNA methyltransferase depletion and DNA damage in patients with advanced melanoma treated with temozolomide alone or with lomeguatrib. British Journal of Cancer 100(8):1250-1256.

23. Mhaidat, N., Thorne, R., Zhang, X. and Hersey, P. (2008). Involvement of endoplasmic reticulum stress in Docetaxel-induced JNK-dependent apoptosis of human melanoma. Apoptosis 13(12): 1505-1512.

24. Thompson, J.F., Hersey, P., and Wachter, E. (2008). Chemoablation of metastatic melanoma using intralesional Rose Bengal. Melanoma Research 18(6):40411. (2.225)

25. Eggermont, A.M., Suciu, S., Santinami, M., Testori, A., Kruit, W.H., Marsden, J., Punt, C.J., Sales, F., Gore, M., Mackie, R., Kusic, Z., Dummer, R., Hauschild, A., Musat, E., Spatz, A.,

27

Keilholz, U., and EORTC Melanoma Group. (2008). Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 372(9633):117-126. (IF: 28.628)

26. Jiang, C.C., Lucas, K., Avery-Kiejda, K.A., Wade, M., de Bock, C.E., Thorne, R.F., Allen, J., Hersey, P., and Zhang, X.D. (2008). Up-Regulation of Mcl-1 is Critical for Survival of Human Melanoma Cells Upon ER Stress. Cancer Research 68(16)6708-6717. (IF: 7.672)

27. Hersey, P., and Zhang, X.D. (2008). Adaptation to ER stress as a driver of malignancy and resistance to therapy in human melanoma. Pigment Cell and Melanoma Research 21(3):358-367. (IF: 4.288)

28. Moncrieff, M., Shannon, K., Hong, A., Hersey, P., and Thompson, J. (2008). Dramatic reduction of chronic lymphoedema of the lower limb with sorafenib therapy. Melanoma Research 18(2):161-162. (IF: 2.225)

29. Hersey, P., Halliday, G.M., Farrelly, M.L., DeSilva, C., Lett, M., and Menzies, S.W. (2008). Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma. Cancer Immunol. Immunotherapy 57:1037-1051. (IF: 4.313)

30. Hauschild, A., Agarwala, S.S., Trefzer, U., Hogg, D., Robert, C., Hersey, P., Eggermont, A., Grabbe, S., Gonzalez, R., Gille, J., Peschel, C., Schadendorf, D., Garbe, C., O’Day, S., Daud, A., White, M., Xia, C., Patel, K., Kirkwood, J., and Hersey, P. (2009). Phase III randomized, placebo-controlled study of Sorafenib in combination with Carboplatin and Paclitaxel in second-line treatment in patients with unresectable stage III or stage IV melanoma. J. Clin. Oncol. 27:2823-2830.

31. Mhaidat, N.M., Thorne, R.F., de Bock, C.E., Zhang, X.D., and Hersey, P. (2008). Melanoma cell sensitivity to Docetaxel-induced apoptosis is determined by class III β-tubulin levels. FEBS Letters 582:267-272. (IF: 3.263)

32. Zhang, L.J., Hao, Y.Z., Hu, C.S., Ye, Y., Xie, Q.P., Thorne, R.F., Hersey, P., and Zhang, X.D. (2008). Inhibition of apoptosis facilitates necrosis induced by cisplatin in gastric cancer cells. Anti-Cancer Drugs 19(2):159-166. (IF: 2.245)

33. Chen, L.H., Jiang, C.C., Watts, R., Thorne, R.F., Kiejda, K.A., Zhang, X.D., and Hersey, P. (2008) Inhibition of ER stress-induced apoptosis of human melanoma cells by the ARC protein. Cancer Research 68(3):834-842. (IF: 7.672)

34. Avery-Kiejda, K.A., Zhang, X.D., Adams, L.J., Vojtesek, B., Lane, D.P., Scott, R.J., and Hersey, P. (2008) Small molecular weight variants of p53 are expressed in human melanoma cells and are differentially regulated by cisplatin. Clinical Cancer Research 14(6):1659-1668. (IF: 6.250)

35. Zhu, B., Wang, P., Zhang, X.D., Jiang, C.C., Chen, L.H., Avery-Kiejda, K.A., Watts, R., and Hersey, P. (2008) Activation of Jun N-terminal kinase is a mediator of vincristine-induced apoptosis of melanoma cells. Anti-Cancer Drugs 19(2):189-200. (IF: 2.245)

36. Mhaidat, N.M., Zhang, X.D., Allen, J., Avery-Kiejda, K.A., Scott, R.J., and Hersey, P. (2007). Temozolomide induces senescence but not apoptosis in human melanoma cells. British Journal of Cancer 97:1225-1233. (IF: 4.459)

37. Mhaidat, N., Thorne, R.F., Zhang, X.D., and Hersey, P. (2007) Regulation of docetaxel-induced apoptosis of human melanoma cells by different isoforms of protein kinase C. Molecular Cancer Research 5:1073-1081. (IF: 4.759)

28

38. Chen, L.H., Jiang, C.C., Kiejda, K.A., Wang, Y.F., Mhaidat, N., Thorne, R., Zhang, X.D., and Hersey, P. (2007) Thapsigargin sensitizes human melanoma cells to TRAIL-induced apoptosis by up-regulation of TRAIL-R2 through the unfolded protein response. Carcinogenesis 28:2328-2336. (IF: 5.406)

39. Jiang, C.C., Chen, L.H., Kiejda, K.A., Gillespie, S., Wang, Y.F., Zhang, X.D., and Hersey, P. (2007) Inhibition of MEK/ERK sensitizes human melanoma cells to endoplasmic reticulum stress-induced apoptosis by enhancing caspase-4 activation. Cancer Res. 67(20):9750-9761. (IF: 7.672.)

40. Wang, Y.F., Jiang, C.C., Kiejda, K.A., Gillespie, S., Zhang, X.D., and Hersey, P. (2007). Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1. Clinical Cancer Research 13(16) 4934-4942. (IF: 6.250)

41. Jiang, C.C., Chen, L.H., Gillespie, S., Kiejda, K.A., Mhaidat, N.M., Wang, Y.F., Thorne, R., Zhang, X.D., and Hersey, P. (2007) Tunicamycin sensitizes human melanoma cells to TRAIL-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response. Cancer Res. 67(12):5880-5888. (IF: 7.672).

42. Ranson, M., Hersey, P., Thompson, D., Beith, J., McArthur, G.A., Haydon, A., Davis, I., Kefford, R., Mortimer, P., Harris, P., Baka, S., Seebaran, A., Sabharwal, A., Watson, A.J., Margison, G.P., and Middleton, M.R. (2007) A randomised trial of the combination of lomeguatrib and temozolomide versus temozolomide alone in chemo-naïve patients with metastatic cutaneous melanoma. J. Clinical Oncology 25:2540-2545. (IF: 13.598)

43. Zhuang, L., Lee, C.S., Scolyer, R.A., McCarthy, S.W., Zhang, X.D., Thompson, J.F., and Hersey, P. (2007) Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Modern Pathology 20:416-426. (IF: 4.286)

44. Mhaidat, N.M., Zhang, X.D., Jiang, C.C. and Hersey, P. (2007) Docetaxel-induced apoptosis of human melanoma is mediated by activation of JNK and inhibited by the MAPKinase ERK1/2 pathway. Clinical Cancer Research 13:1308-1314. (IF: 6.250)

45. Mhaidat, N.M., Wang Y., Kiejda, K., Zhang, X.D., and Hersey P. (2007) Docetaxel- induced Apoptosis in Melanoma Cells is dependent on Activation of Caspase 2. Mol Cancer Therapeutics 6:752-761. (IF: 4.800).

46. Zhang, X.D., Wu, J.J., Gillespie, S., Borrow, J., and Hersey, P. (2006) Cross resistance of melanoma to trail-induced apoptosis and chemotherapy. Update on Cancer Therapeutics 1:435-441. (IF: Online journal)

47. Gillespie, S., Borrow, J., Zhang, X.D., and Hersey, P. (2006) Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells. Apoptosis 11(12):2251-2265 (IF: 4.497)

48. Yu, F., Watts, R., Zhang, X.D., Borrow, J.M., and Hersey, P. (2006) Involvement of BH3 only proapoptotic proteins in mitochondrial dependent Phenoxodiol induced apoptosis of human melanoma cells. Anticancer Drugs 17(10):1151-1161 (IF: 1.97).

49. Bedikian, A., Millward, M., Pehamberger, H., Conry, R., Gore, M., Sterry, W., Pavlick, A.C., DeConti, R., Hersh, E.M., Hersey, P., Kirkwood, J.M., Haluska, F.G., the Oblimersen Melanoma Study Group. (2006) Bcl-2 antisense (Oblimersen Sodium) plus Dacarbazine in patients with advanced melanoma. J. Clin. Oncol. 24:4738-4745.

29

50. Zhuang, L., Lee, C.S., Scolyer, R.A., McCarthy, S.W., Zhang, X.D., Thompson, J.F., Screaton, G., and Hersey, P. (2006) Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Human Pathology 37:1286-1294 (IF: 3.043)

51. Hersey, P., Zhuang, L., and Zhang, X.D. Current strategies in overcoming resistance of cancer cells to apoptosis, melanoma as a model. (2006) International Review of Cytology 251:131-158. (IF: 5.988)

52. Hersey, P. Apoptosis and melanoma: how new insights are effecting the development of new therapies for melanoma. (2006) Current Opinion in Oncology 18:189-196. (IF: 3.043)

53. Zhang, X.D., Wu, J.J., Gillespie, S.K., Borrow, J.M., and Hersey, P. (2006) Human melanoma cells selected for resistance to apoptosis by prolonged exposure to TRAIL are more vulnerable to necrotic cell death induced by Cisplatin. Clin. Cancer Res. 12(4):1355-1364. (IF: 6.250)

54. Millward, M.J., Joshua, A., Kefford, R., Aamdal, S., Thomson, D., Hersey, P., Toner, G. and Lynch, K. (2005) Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma. Invest. New Drugs 23(3):253-6. (IF: 2.41)

55. Zhuang, L., Lee, C.S., Scolyer, R.A., McCarthy, S.W., Palmer, A.A., Zhang X.D., Thompson, J.F., Bron, L.P. and Hersey, P. (2005) Activation of the extracellular-signal related kinase (ERK) pathway in human melanoma. J. Clin. Pathology 58(11):1163-1169. (IF: 2.245)

56. Wu, J.J., Zhang, X.D., Gillespie, S. and Hersey, P. (2005) Selection for TRAIL resistance results in melanoma cells with high proliferative potential. FEBS Letters 579(9):1940-1944. (IF: 3.263)

57. Allen, J.D., Zhang, X.D., Scott, C.L., Boyle, G.M., Hersey, P. and Strasser, A. (2005) Is Apaf-1 expression frequently abrogated in melanoma? (Letter) Cell Death & Differentiation 12(6):680-1. (IF: 8.254)

58. Byrne, C.M., Thompson, J.F., Johnston, H., Hersey, P., Quinn, M.J., Hughes, T.M. and McCarthy, W.H. (2005) Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Research 15:45-51. (IF: 2.225)

59. Gillespie, S., Zhang, X.D. and Hersey, P. (2005) Variable expression of protein kinase C epsilon in human melanoma cells regulates sensitivity to TRAIL-induced apoptosis. Molecular Cancer Therapeutics 4(4):668-76. (IF: 4.800)

60. Bron, L.P., Scolyer, R.A., Thompson, J.F. and Hersey, P. (2004) Histological expression of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in human primary melanoma. Pathology 36(6):561-565. (IF: 3.043)

61. Gillespie, S.K., Zhang, X.D. and Hersey, P. (2004) Ingenol 3-angelate induces dual modes of cell death and differentially regulates TRAIL-induced apoptosis in melanoma cells. Molecular Cancer Therapeutics 3:1651-1658. (IF: 4.800)

62. Hersey, P., Menzies, S.W., Coventry, B., Nguyen, T., Farrelly, M., Collins, S., Hirst, D., and Johnson, H. (2005) Phase I/II study of immunotherapy with T cell peptide epitopes in patients with stage IV melanoma. Cancer Immunology Immunotherapy 54(3): 208-218. (IF: 4.313)

30

63. Ishri, R., Menzies, S., Hersey, P., and Halliday, G.M. (2004) Rapid downregulation of antigen processing enzymes in exi vivo generated human monocyte derived dendritic cells occur endogenously in extended cultures. Immunol. Cell Biol. 82(3):239-246. (IF: 1.854)

64. Pavey, S., Johannsen, P., Packer, L., Taylor, J., Stark, M., Pollock, P.M., Walker, G.J., Boyle, G., Harper, U., Cozzi, S., Hansen, K., Yudt, L., Schmidt, C., Hersey, P., Ellem, K.A.O., O’Rourke, M.G.E., Parsons, P.G., Meltzer, P., Ringner, M., and Hayward, N.K. (2004) Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 23(23): 4060-7. (IF: 6.444) (C: 2)

65. Zhang, X.D., Gillespie, S.K., Borrow, J.M. and Hersey, P. (2004) The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol. Cancer Ther. 3(4):425-435. (IF: 5.581)

66. Zhang, X.Y., Zhang, X.D., Borrow, J.M., Nguyen, T. and Hersey, P. (2004) Translational control of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor expression in melanoma cells. J. Biol. Chem. 279:10606-10614. (IF: 6.482)

67. Shafren, D.R., Au, G., Nguyen, T., Newcombe, N.G., Haley, E.S., Beagley, L., Johansson, E.S., Hersey, P. and Barry, R.D. (2004) Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, Coxsackievirus A21. Clinical Cancer Research 10. (IF: 6.250) (C: 3)

68. Hersey, P. (2004) Vaccinia viral lysates in immunotherapy of melanoma. In: Virus Therapy of Human Cancers. Eds: Sinkovics, J.G. and Horvath, J.C. Marcel Dekker, Inc. New York. Pages 691-712.

69. Hersey, P., Zhang, X.Y. and Zhang, X.D. (2004) Regulation of TRAIL receptor expression in human melanoma. In: Death Receptors in Human Cancer. Eds: El-Deiry, W.S. Humana Press. New Jersey. Pages 175-187.

70. Hersey, P., Menzies, S.W., Halliday, G.M., Nguyen, T., Farrelly, M.L., De Silva, C. and Lett, M. (2004) Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol. Immunother. 53:125-134, 2004. (IF: 4.086) (C: 3)

71. Zhang, X.D., Gillespie, S.K. and Hersey, P. (2004) Staurosporine induces apoptosis of melanoma by both caspase dependent and independent apoptotic pathways. Molecular Cancer Therapeutics 3(2): 187-197. (IF: 4.800) (C: 1)

72. Hersey, P. (2004) Immunotherapy of non-resected melanoma. In: Textbook of Melanoma. Eds: Thompson, J.F., Morton, D.L. and Kroon, BBR. Martin Dunitz/Taylor and Francis. London. 57:559.

73. Hersey, P., Morton, D.L. and Eggermont, A. (2004) Adjuvant therapy for high-risk primary melanoma and resected metastatic melanoma. In: Textbook of Melanoma. Eds: Thompson, J.F., Morton, D.L. and Kroon. BBR. Martin Dunitz/Taylor and Francis. London. 55:573.

74. Hersey, P. (2004) Immunotherapy of melanoma: principles. In: Textbook of Melanoma. Eds: Thompson, J.F., Morton, D.L. and Kroon. BBR. Martin Dunitz/Taylor and Francis. London. 54:559.

75. Hersey, P. and Zhang, X.D. (2003) Resistance of follicular lymphoma cells to chemotherapy is more than just Bcl-2. Cancer Biology & Therapy 2(5):541-3. (IF: 3.024)

76. Zhang, X.D., Gillespie, S.K., Borrow, J.M. and Hersey, P. (2003) The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF related

31

apoptosis inducing ligand (TRAIL) induced apoptosis. Biochemical Pharmacology 66:1537-1545. (IF: 2.993) (C: 5)

77. Hersey, P. and Zhang, X.D. (2003) Overcoming resistance of melanoma cells to apoptosis. Journal of Cellular Physiology 196:9-18. (IF: 5.463) (C: 10)

78. Gray. C.P., Arosio, P. and Hersey, P. (2003) Association of increased levels of heavy chain ferritin with increased CD4+CD25+ regulatory T cells in patients with melanoma. Clinical Cancer Research 9:2551-2559. (IF: 6.511) (C:1)

79. Zhang, X.D., Borrow, J.M., Zhang, X.Y., Nguyen, T. and Hersey, P. (2003) Activation of ERK1/2 protects melanoma cells from TRAIL induced apoptosis by inhibiting SMAC/diablo release from mitochondria. Oncogene 22:2869-2881. (IF: 6.495) (C: 5)

80. Hersey, P. (2003) Adjuvant therapy for high risk primary and resected metastatic melanoma. Internal Medicine Journal 33:33-43. (IF: 0.552) (C: 5)

81. Hanrahan, P.F., D’Este, C.A., Menzies, S.W., Plummer, A. and Hersey, P. (2002) A randomised trial of skin photography as an aid to screening skin lesions in older males. J. Med. Screening 9:128-132. (IF: 1.867) (C: 4)

82. Hersey, P., Coates, A.S., McCarthy, W.H., Thompson, J.F., Sillar, R.W., McLeod, R., Gill, G., Coventry, B. and Dillon, H. (2002) Adjuvant immunotherapy of patients with high risk melanoma with vaccinia viral lysates of melanoma. Results of a randomised trial. J Clin Oncol 20:4181-4190. (IF: 10.864) (C: 12)

83. Hersey, P. (2002) “Immunotherapy”. In: World Cancer Report. Eds: Stewart, B.W. IARC 210-214.

84. Hersey, P. (2002) Advances in non-surgical treatment of melanoma. Expert Opin. Investig. Drugs 11(1):75-85. (IF: 3.117) (C: 4)

85. Gray, C.P., Arosio, P and Hersey, P. (2002) Heavy chain ferritin activates regulatory T cells by cells by induction of changes in dendritic cells. Blood 99:3326-3334. (IF: 10.120) (C: 13)

86. Saleh, F.H., Crotty, K.A., Hersey, P. and Menzies, S.W. (2001) Primary melanoma tumour regression associated with an immune response to the tumour-associated antigen melan-A/MART-1. Int. J. Cancer 94(4):551-557. (IF: 4.375) (C: 11)

87. Hersey, P. and Zhang, X.D. (2001) How melanoma cells evade TRAIL induced apoptosis. Nature Reviews Cancer 1:142-150. (IF: 33.954) (C: 36)

88. Zhang, X.D., Zhang, X.Y., Gray, C.P., Nguyen, T. and Hersey, P. (2001) TRAIL induced apoptosis of human melanoma is regulated by Smac/DIABLO release from mitochondria. Cancer Research 61:7339-7348. (IF: 8.649) (C: 66)

89. Gray, C.P., Franco, A.V., Arosio, P. and Hersey, P. (2001) Immunosuppressive effects of melanoma derived heavy chain ferritin is dependent on stimulation of IL-10 production. Int. J. Cancer 92(6):843-850. (IF: 4.375) (C: 7)

90. Hanrahan, P., Menzies, S.W., D’Este, K., Plummer, A. and Hersey, P. (2000) Participation of older males in a study on photography as an aid to early detection of melanoma. Aust. N.Z. J. Public Health 24:615-618. (C: 5)

91. Zhang, X.D., Nguyen, T., Thomas, W.D., Sanders, J.E. and Hersey, P. (2000) Mechanisms of resistance of normal cells to TRAIL induced apoptosis varies between different cell types. FEBS Letters 482:193-199. (IF: 3.609) (C: 66)

32

92. Franco, A.V., Zhang, X.D., Van Berkel, E., Sanders, J.E., Zhang, X.Y., Thomas, W.D., Nguyen, T. and Hersey, P. (2001) The role of NF-B in TRAIL induced apoptosis of melanoma cells. J. Immunol. 166:5337-5345. (IF: 6.702) (C: 36)

93. Thomas, W.D., Zhang, X.D., Franco, A.V., Nguyen, T. and Hersey, P. (2000) TNF-related apoptosis-inducing ligand-induced apoptosis of melanoma is associated with changes in mitochondrial membrane potential and perinuclear clustering of mitochondria.J. Immunol. 165:5612-5620. (IF: 6.702) (C: 37)

94. Nguyen, T., Thomas, W.D., Zhang, X.D., Gray, C. and Hersey, P. (2000) Immunologically mediated tumor cell apoptosis. The role of TRAIL in T cell and cytokine mediated responses to melanoma. Forum 10:243-252. (C: 4)

95. Nguyen, T., Zhang, X.D. and Hersey, P. (2001) Relative Resistance of fresh isolates of melanoma to TRAIL induced apoptosis. Clinical Cancer Research 7:966S-973S. (IF: 6.511) (C: 19)

96. Hersey, P. (2001) Will vaccines really work for melanoma? In: “Melanoma: Critical Debates” Eds: Newton-Bishop and Gore. Blackwell Science (In press).

97. Curry, B.J., Myers, K. and Hersey, P. (2000) Utility of tests for circulating melanoma cells (CMCs), in identifying patients who develop recurrent melanoma. In: Recent Results in Cancer Research 158:211-230.

98. Zhang, X.D., Franco, A.V., Nguyen, T., Gray, C.P. and Hersey, P. (2000) Differential localization and regulation of death and decoy receptors for TRAIL in human melanoma cells. J. Immunol. 164:3961-3970. (IF: 6.702) (C: 70)

99. Hersey, P. (1999) Advances in management of melanoma. A. & N.Z. J. Med. 29:292-299.

100. Zhang, X. and Hersey, P. (1999) Expression of catenins and p120cas in melanocytic naevi and cutaneous melanoma: deficient -catenin expression is associated with melanoma progression. Pathology 31:239-246.

101. Serrone, L. and Hersey, P. (1999) The chemoresistance of human malignant melanoma: an update. Melanoma Research 9:1-8.

102. Bonevski, B., Sanson-Fisher, R., Hersey, P., Paul, C. and Foot, G. (1999) Assessing the perceived needs of patients attending an outpatient melanoma clinic. J. Psychosocial Oncology 17:101-118.

103. Curry, B. and Hersey, P. (1999) Examination of the utility of assays for S100 in prediction of recurrence from melanoma. Melanoma Research 9:1-11.

104. Curry, B., Myers, K. and Hersey, P. (1999) MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared to locoregional metastases. J. Clin. Oncol. 17:2562-2572.

105. Hersey, P. (1999) Cancer vaccines in therapy of cancer. In: Primer on Tumor Immunology. Eds: Parmiani, G. and Lotze, M. Harwood Academic Press. (In press).

106. Zhang, X.D., Franco, A., Myers, K., Gray, C., Nguyen, T. and Hersey, P. (1999) Relation of TRAIL receptor and FLIP expression to TRAIL induced apoptosis of melanoma.Cancer Research 59:2747-2753.

33

107. Ralph, S.J., Wong, L.H., Hatzinisiriou, I., Estcount, M., Hersey, P. and Devenish, R. (1998) Revising interferons - prodigies among the cytokines. Today’s Life Science, November/December: 37-43.

108. Barrio, M.M., Bravo, A.I., Portela, P., Hersey, P. and Mordoh, J. (1998) A novel monoclonal antibody to human melanoma-associated antigen CD63/ME491 recognizes a new epitope both in primary and metastatic melanoma. Hybridoma 17:355-364.

109. Hersey, P. (1999) Impediments to successful immunotherapy. Pharmacology and Therapeutics 81:111-119.

110. Burton, R.C., Howe, C., Adamson, L., Reid, A.L., Hersey, P., Watson, A., Watt, G., Relic, J., Holt, D., Thursfield, V., Clarke, P. and Armstrong, B.K. (1998) General practitioner screening for melanoma: sensitivity, specificity, and effect of training. J. Med. Screening 5:156-161.

111. Thomas, W.D. and Hersey, P. (1998) TRAIL induces apoptosis in Fas ligand resistant melanoma cells and mediates CD4 T cell killing of target cells. J. Immunol. 161:2195-2200. (IF: 6.702) (C: 144)

112. Walpole, E.T., Hersey, P., Thomson, D. and McLeod, G.R.C. (1997) Recombinant interferon-2a plus 5-fluorouracil for the treatment of metastatic melanoma. Melanoma Research 7:513-516.

113. Wong, L.H., Krauer, K.G., Hatzinisiriou, I., Estcourt, M.J., Hersey, P., Nguyen, D.T., Edmondson, S., Devenish, R.J. and Ralph, S.J. (1997) Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3. J Biol. Chem. 272:28779-28785.

114. Hanrahan, P.F., Hersey, P. and D'Este, C.A. (1998) Presentation of older people with thick melanoma is associated with failure to notice changes of melanoma, as well as the site and histological type of their melanoma. Med J Aust 169:410-414.

115. Curry, B.J., Myers, K. and Hersey, P. (1998) PCR detection of melanoma cells in the circulation. Relation to clinical stage, surgical treatment and recurrence from melanoma. J Clin Oncol 16:1760-1769.

116. Smith, M., Bleijs, R., Radford, K. and Hersey, P. (1997) Immunogenicity of CD63 in a patient with melanoma. Melanoma Research 7(Suppl 2):5161-5168.

117. Elder, G.J., Hersey, P. and Branley, P. (1997) Remission of transplanted melanoma - clinical course and tumour cell characterisation. Clinical Transplantation 11(6):565-568.

118. Hersey, P. (1997) Melanoma Vaccines. Prospects for the treatment of melanoma. Expert Opinion On Investigational Drugs 6:267-277.

119. Thomas, W. and Hersey, P. (1998) CD4 T cells kill melanoma cells by mechanisms that are independent of Fas (CD95). Int J Cancer 75:384-390.

120. Hanrahan, P.F., Hersey, P., Menzies, S.W., Watson, A.B. and D'Este, K. (1997) Examination of the ability of people to identify early changes of melanoma in computer altered pigmented skin lesions. Archives of Dermatology 133:301-311.

121. Radford, K.J., Thorne, R.F. and Hersey, P. (1997) Regulation of adhesion and motility by the CD63 molecule in a human cell line. J. Immunol. 158:3353-3358.

34

122. Nguyen, T., Smith, M. and Hersey, P. (1997) Contrasting effects of T cell growth factors on T cell responses to melanoma in vitro. Cancer Immunol. Immunother. 43:345-354.

123. Thomas, W.D., Smith, M.J., Si, Z. and Hersey, P. (1996) Expression of the costimulatory molecule CD40 on melanoma cells. Int. J. Cancer 68:795-801.

124. Grulich, A.E., Bataille, V., Swerdlow, A.J., Newton-Bishop, J.A., Cuzick, J., Hersey, P. and McCarthy, W.H. (1996) Naevi and pigmentary characteristics as risk factors for melanoma in a high risk population: a case-control study in New South Wales, Australia. Int. J. Cancer 67:485-491.

125. Robinson, W.A., Elefanty, A.G. and Hersey, P. (1996) Expression of the tumour suppressor genes p15 and p16 in malignant melanoma. Melanoma Research 6:285-289.

126. Radford, K., Thorn, R. and Hersey, P. (1996) CD63 associates with transmembrane 4 superfamily members, CD9 and CD81, and with ß1 integrins in human melanoma. Biochem Biophys Res Commun 222:13-18.

127. Si, Z., Hersey, P. and Coates, A.S. (1996) Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Melanoma Research 6:247-255.

128. Hersey, P. (1996) Melanoma peptides in treatment of melanoma. Life Science 8:34-38.

129. Curry, B.J., Smith, M.J. and Hersey, P. (1996) Detection and quantitation of melanoma cells in the circulation of patients. Melanoma Research 6(1):45-54.

130. Chapman, R.S., Cooper, K.D., De Fabo, E.C., Frederick, J.E., Gelatt, K.N., Hammond, S.P., Hersey, P., Koren, H.S., Ley, R.D., Noonan, F., Rusch, G.M., Sarasin, A., Selgrade, M.J., Sobolev, I., Ward, B.J. and Werkema, T.E. (1995) Solar ultraviolet radiation and the risk of infectious disease: Summary of a workshop. Photochemistry and Photobiology 61:223-247.

131. Hersey, P. Interferon in skin tumors. Melanoma and basal cell carcinoma. (1997). In: Clinical Applications of the Interferons. Eds. Penny, R. and Stuart-Harris, R. Chapman and Hall, London.p. 169-183.

132. Radford, K.J., Smith, M.J., Mallesch, J. and Hersey, P. (1995) Suppression of human melanoma cell growth and metastasis by the melanoma associated antigen CD63 (ME491). Int. J. Cancer 62:631-635.

133. Hanrahan, P.F., Hersey, P. and Watson, A.B. (1995) Evaluation of the effect of an educational brochure on knowledge and early detection of melanoma. Aust. J. Public Health 19:270-274.

134. Hersey, P., Si, Z., Smith, M.J. and Thomas, W.D. (1994) Expression of the costimulatory molecule B7 on melanoma cells. Int. J. Cancer 58:527-532.

135. Hersey, P. (1994) Melanoma Vaccines. Current Status and Future Prospects. Drugs 47:373-382.

136. Byles, J.E., Hennrikus, D., Sanson-Fisher, R. and Hersey, P. (1994) Reliability of naevus counts in identifying individuals at high risk of malignant melanoma. Brit. J. Dermatol. 130:51-56.

137. Thomson, D.B., Adena, M., McLeod, G.R.C., Hersey, P., Gill, P.G., Coates, A.S., Olver, I., Kefford, R.F., Lowenthal, R.M., Beadle, G.F., Walpole, E.T., Boland, K. and Kingston, D.

35

(1993) Interferon alpha-2a does not improve response or survival when combined with dacarbazine alone in metastatic malignant melanoma: Results of a multi-institutional Australian randomised trial. Melanoma Res. 3:133-138.

138. Coates, A., Thomson, D., McLeod, G.R.M., Hersey, P., Gill, P.G., Olver, I.N., Kefford, R., Lowenthal, R.M., Beadle, G. and Walpole, E. (1993) Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur. J. Cancer 29A(12):1731-1734.

139. Hersey, P. (1993) Cellular therapy. Current Opinion in Oncology 5:1049-1054.

140. Hersey, P. (1993) Evaluation of vaccinia viral lysates as therapeutic vaccines in treatment of melanoma. In: Specific Immunotherapy of Cancer with Vaccines. Ed. Bystryn, J.C., Ferrone, S. and Livingston, P. Ann NY Acad. Sci., Vol. 690, p. 167-178.

141. Burton, R.C., Coates, M.S., Hersey, P., Roberts, G., Chetty, M.P., Chen, S., Hayes, M.H., Howe, C.G. and Armstrong, B.K. (1993) An analysis of a melanoma epidemic. Int. J. Cancer 55:765-770.

142. Hersey, P., Strong, T., Grant, D. and Marish, Z. (1994) Risk Factors for presentation with thick primary melanoma include older age, male sex, smoking and may include occupation in certain industries. In: Epidemiologic Aspects of Malignant Melanoma. Ed. Gallagher, R.P., Elwood, J.M. Kluwer Academic Publishers, Boston. p. 273-288.

143. Hersey, P. (1993) The current status of immunotherapy for melanoma. Cancer Forum, July, 1993, 101-106.

144. Chen, Q., Daniel, V., Maher, D., Nguyen, T. and Hersey, P. (1994) Production of IL-10 by melanoma cells. Examination of its role in immunosuppression mediated by melanoma. Int. J. Cancer 56:755-760.

145. Chen, Q., Nguyen, T. and Hersey, P. (1994) HLA-A1 restricted recognition of melanoma by cytotoxic T cells. Cancer Immunol. and Immunother. 34:385-393.

146. Si, Z. and Hersey, P. (1994) Immunohistological examination of the relation between metastatic potential and expression of adhesion molecules and "selectins" on melanoma cells. Pathology 26:6-15.

147. Si, Z. and Hersey, P. (1993) Expression of the neuroglandular antigen and analogues in melanoma. CD9 and MHC class I antigens appear inversely related to metastatic potential of melanoma. Int. J. Cancer 54:37-43.

148. Hersey, P., Magrath, H. and Wilkinson, F. (1992) Development of an in vitro system for the analysis of ultraviolet radiation induced suppression of natural killer cell activity. Photochem. & Photobiology 57:279-284.

149. Hersey, P. (1992) Cytokines in melanoma therapy. In: Interferons and Cytokines 21:6-11.

150. Chen, Q. and Hersey, P. (1992) MHC restricted responses of CD8+ and CD4+ T cell clones from regional lymph nodes of melanoma patients. Int. J. Cancer 51:218-224. (IF: 4.375) (C: 37)

151. Hersey, P. (1992) Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma. World J. Surg. 16:251-260.

152. Hersey, P. (1992) Examination of the scientific basis for vaccines in treatment of melanoma. Vaccine Research 1:357-372.

36

153. Hersey, P., McLeod, G.R.C. and Thomson, D.B. (1991) Treatment of advanced malignant melanoma with recombinant interferon alfa-2a in combination with DTIC. Long term follow up of two phase II studies. Brit. J. Haematol. Supplement 1, 79:60-66.

154. Hersey, P., Sillar, R.W., Howe, C.G., Burton, R.C., Darbar, S.V., Foster, H.M., Collins, S.M., Bradley, D.E. and Owens, D. (1991) Factors related to presentation of patients with thick primary melanomas. Med. J. Aust. 154:583-7.

155. Hersey, P. (1990) Immunotherapy of malignant melanoma. Cancer Forum 14:24-31.

156. Hersey, P. (1993) Vaccinia viral lysates in treatment of melanoma. In: Biological approaches to Cancer Treatment: Biomodulation. Ed. Mitchell, M.S. McGraw Hill, New York. p. 302-325.

157. Hersey, P., Werkman, H. and Edwards, A.E. (1990) Western blot analysis of serological responses following immunization with vaccinia viral lysates of melanoma cells. Int. J. Cancer 46:612-617.

158. Hersey, P. (1989) Detection of immunity to human neoplasms. Current Opinion in Immunology 1:895-899.

159. Hersey, P. and MacDonald, M. (1990) Fc receptors as mediators of MHC-unrestricted lysis by activated type 2 T cells. In: 6th Int. NK Workshop. Ed. Schmidt, R.E. S. Karger, AG Basel. p. 94-98.

160. Hersey, P., Meldrum, C., Daniels, V., Werkman, H. and Sneddon, D. (1990) Characterization of melanoma antigens recognized by human T cells. In: Cellular Immunity and Immunotherapy of Cancer, UCLA Symposia on Molecular and Cellular Biology, New Series, Volume*. Ed. Lotze, M.T. and Finn, O.J. Wiley-Liss, Inc., New York, NY. p. 343-349.

161. Hersey, P. and Jamal, O. (1990) Immunohistological relation between DR antigen expression on melanoma cells and infiltration by CD8+ T cells. Pathology 22:133-139.

162. Hersey, P. (1990) Biological agents in treatment of cancer. A. & N.Z. J. Med. 20:85-98.

163. Schibeci, S., Hersey, P. and Cheresh, D. (1989) Potentiation of interleukin 2 (IL2) production and binding of IL2 by monoclonal antibodies to the gangliosides GD3 and GD2. Cancer Immunol. Immunotherapy 29(2):109-117.

164. Hersey, P. (1990) Current status of active specific immunotherapy of melanoma. In: Therapy of advanced malignant melanoma. Ed. Rumpke, P. S. Karger, AG Basel. p. 183-200.

165. Hersey, P., Meldrum, C. and MacDonald, M. (1990) Identification of antigens recognized by T cells. In: Focus on Laboratory Methods in Immunology. Ed. Zola, H. CRC Press Inc. p. 185-193.

166. Hersey, P., Schibeci, S. and Cheresh, D. (1989) The role of protein kinase C (PKC) intracellular calcium and cyclic nucleotides in the augmentation of lymphocyte responses by monoclonal antibodies to the gangliosides GD3 and GD2. Cell. Immunol. 119:263-278.

167. Hersey, P., McLeod, R.C., Thomson, D.B. and DeGaris, S.T. (1987) Phase I/II study of tolerability and efficacy of recombinant interferon (Roferon) with Dacarbazine (DTIC) in

37

advanced malignant melanoma (MM). In "Progress in Chemotherapy". Anticancer Section. Ed. B Berkarda, Istanbul, and H.P. Kuemmerle, Munich/Tokyo/Shanghai.

168. Hersey, P. and Jamal, O. (1988) Expression of the gangliosides GD3 and GD2 on lymphocytes in tissue sections of melanoma. Pathology 21:51-58.

169. Zardawi, I.M., Jarvis, L. and Hersey, P. (1988) DNA ploidy in thin melanoma. Pathology 20:243-246.

170. Tamat, S.R., Moore, D.E., Patwardhan, A. and Hersey, P. (1989) Boronated monoclonal antibody 225.28S for potential use in neutron capture therapy of malignant melanoma. Pigment Cell Res. 2:281-285.

171. Hersey, P., MacDonald, M., and Werkman, H. (1988) Western blot analysis of melanoma antigens recognized by T lymphocytes. J. Natl. Canc. Inst. 80:826-835. (IF: 13.844) (C: 22)

172. Hersey, P. (1989) Preclinical and phase I studies of monoclonal antibodies in melanoma. Application to Boron neutron capture therapy of melanoma. Pigment Cell Res. 2:264-272.

173. Hersey, P. (1989) "Natural immunity" mediated by activated cytotoxic T lymphocytes. In: Natural Immunity. Ed. Nelson, D.S. Acad. Press, 123-146.

174. McLeod, G.R.C., Thomson, D.B. and Hersey, P. (1987) Recombinant interferon alfa-2a in advanced malignant melanoma. A phase I-II study in combination with DTIC. Int. J. Cancer Supplement 1, 31-35.

175. Hersey, P., MacDonald, M., Henderson, C., Schibeci, S., D'Alessandro, G., Pryor, M. and Wilkinson, F. (1988) Suppression of natural killer cell activity in humans by radiation from solarium lamps depleted of UVB. J. Invest. Dermatol. 90:305-312.

176. Hersey, P., Jamal, O., Henderson, C., Zardawi, I. and D'Alessandro, G. (1988) Expression of the Gangliosides GM3, GD3 and GD2 in tissue sections of normal skin, naevi, primary and metastatic melanoma. Int. J. Cancer 41:336-343.

177. Hersey, P., Edwards, E., Coates, A., Shaw, H., McCarthy, W.H. and Milton, G.W. (1987) Evidence that treatment with vaccinia melanoma cell lysates may improve survival in patients with Stage II melanoma. Cancer Immunol. Immunotherapy 25(3): 257-265.

178. D'Alessandro, G., Zardawi, I., Grace, J., McCarthy, W.H. and Hersey, P. (1987) Immunohistological evaluation of MHC Class I and II antigen expression on naevi and melanoma - relation to biology of melanoma. Pathology 19:339-346.

179. Hersey, P. and Bolhuis, R.L.H. (1987) Factors influencing the generation of "non specific" MHC unrestricted cytotoxic T cells and receptors involved in their activity. Immunol. Today 8:233-239.

180. Hersey, P., McLeod, G.R.C. and Thomson, D.B. (1986) Recombinant interferon alpha (2A) combined with dacarbazine in treatment of metastatic melanoma. 1986 ISIR-TNO Meeting.

181. Hersey, P., MacDonald, M., Burns, C., Schibeci, S., Matthews, H. and Wilkinson, F. (1987) Analysis of the effect of a sunscreen agent on the suppression of natural killer cell activity induced in human subjects by radiation from solarium lamps. J. Invest. Dermatol. 88:271-276.

38

182. Hersey, P., MacDonald, M., Burns, C. and Cheresh, D.A. (1986) Enhancement of cytotoxic and proliferative responses of lymphocytes from melanoma patients by incubation with monoclonal antibodies against ganglioside GD3. Cancer Immunol. Immunotherapy 15:22-28.

183. Hersey, P., Schibeci, S.D., Townsend, P., Burns, C. and Cheresh, D.A. (1986) Potentiation of interleukin 2, phytohemagglutin and T3 monoclonal antibody (M.Ab) induced lymphocyte responses by M.Abs to GD3. Cancer Res. 46:6083-6090. (IF: 8.649) (C: 77)

184. Hersey, P., Edwards, A., D’Alessandro, G. and MacDonald, M. (1986) Phase II study of vaccinia melanoma cell lysates (VMCL) as adjuvant to surgical treatment of stage II melanoma. II. Effects of cell mediated cytotoxicity and leukocyte dependent antibody activity. Cancer Immunol. Immunother. 22:221-231.

185. Hersey, P. (1986) Effects of electromagnetic radiation on the immune system in mice and man. EOS J. Immunol. And Immunopharmacol. 6:216-222.

186. Hersey, P., MacDonald, M., Schibeci, S. and Burns, C. (1987) Clonal analysis of the nature and specificity of cytotoxic T cells in melanoma patients. In “Cutaneous Melanoma – Status of Knowledge and Future Perspective” Eds. U. Veronesi, N. Cascinelli and M. Santinami. Acad. Press 421-432.

187. Hersey, P., Coates, A., Rallings, M., Hall, C., MacDonald, M., Spurling, A., Edwards, A., McCarthy, W.H. and Milton, G.W. (1986) Comparative study on the effects of recombinant alpha 2 interferon on immune function in patients with disseminated melanoma. J. Biol. Resp. Mod. 5:236-249.

188. Hersey, P., MacDonald, M., Schibeci, S. and Burns, C. (1986) Clonal analysis of cytotoxic T lymphocytes (CTL) against autologous melanoma. Classification based on phenotype, specificity and inhibition by monoclonal antibodies to T cell structures. Cancer Immunol. Immunother. 22:15-23.

189. Hersey, P. (1986) The evolving role of recombinant alpha interferons in the treatment of malignancies. A. & N.Z. J. Med. 16:425-437.

190. Coates, A., Rallings, M., Hersey, P. and Swanson, C. (1986) Phase II study of recombinant alpha-2 interferon in advanced malignant melanoma. J. Interferon Res. 6:01-04.

191. Hersey, P., MacDonald, M., Hall, C., Spurling, A., Edwards, A. and McCarthy, W.H. (1986) Immunological effects of recombinant interferon alpha 2A (rIFN-2A) in patients with disseminated melanoma. Cancer 57:1292-1300.

192. Hersey, P. (1985) Review of melanoma antigens recognized by monoclonal antibodies. Their functional significance and application in diagnosis and treatment of melanoma. Pathology 17:346-354.

193. Hersey, P., Hasic, E., MacDonald, M., Edwards, A., Spurling, A., Coates, A.S., Milton, G.W. and McCarthy, W.H. (1985) Effects of recombinant leukocyte interferon (rIFN-A) on tumour growth and immune responses in patients with metastatic melanoma. Br. J. Cancer 51:815-826.

194. Hersey, P., Murray, E., Grace, J. and McCarthy, W.H. (1985b) Current research on immunopathology of melanoma: Analysis of lymphocyte populations in relation to antigen expression and histological features of melanoma. Pathology 17, 385-391.

39

195. Hersey, P., Bindon, C., Bradley, M. and Hasic, E. (1984) Effect of isoprinosine on interleukin 1 and 2 production and on suppressor cell activity in pokeweed mitogen stimulated cultures of B and T cells. Int. J. Immunopharm. 6:321-328.

196. Hersey, P. and Edwards, A. (1984) Effect of Isoprinosine on natural killer cell activity of blood mononuclear cells in vitro and in vivo. Int. J. Immunopharm. 6:315-320.

197. Hersey, P., Edwards, A., Milton, G.W. and McCarthy, W.H. (1984) No evidence for an association between natural killer cell activity and prognosis in melanoma patients. Natural Immunity and Cell Growth Regulation 3:87-94.

198. Hersey, P. and Balch, C.M. (1984) Current status and future prospects for adjuvant therapy of melanoma. Aust. N.Z. J. Surg. 54:303-316.

199. Frankel, T.L., Mason, R.S., Hersey, P., Murray, E. and Posen, S. (1984) The synthesis of vitamin D metabolites by human melanoma cells. J. Clin. Endocrinol. 57:76-84.

200. Hersey, P., Prendergast, D. and Edwards, A. (1983) Effects of smoking on the immune system. Follow-up studies on normal subjects after cessation of smoking. Med. J. Aust. 2:425-429.

201. Hersey, P. (1983) Immunological effects of radiation from solarium lamps and the sun. Editorial Comment. Med. J. Aust. August 20, 159-160.

202. Hersey, P., Haran, G., Hasic, E. and Edwards, A. (1983) Alteration of T cell subsets and incubation of suppressor T cell activity in normal subjects following exposure to sunlight. J. Immunol. 31:171-174.

203. Hersey, P., Grace, J., Murray, E., Palmer, A. and McCarthy, W.H. (1983) Expression of Thy-1 antigen on human melanoma cells. Int. J. Cancer 32:21-25.

204. Hersey, P., Bindon, C., Czerniecki, M., Wass, J. and McCarthy, W.H. (1983) Inhibition of interleukin 2 production by factors released from tumour cells. J. Immunol. 131:2837.

205. Hersey, P., Bradley, M., Hasic, E., Haran, G., Edwards, A. and McCarthy, W.H. (1983) Immunological effects of solarium exposure in human subjects. Lancet 545-548.

206. Hersey, P., Edwards, A., Murray, E., McCarthy, W.H. and Milton, G.W. (1983) Prognostic significance of leukocyte dependent antibody activity in melanoma patients. J. Natl. Canc. Inst. 71:45-53.

207. Hersey, P., Lawrence, S., Prendergast, D., Bindon, C., Benson, W. and Valk, P. (1983a) Association of Sjogren’s syndrome with C4 deficiency defective reticulo-endothelial function and circulating immune complexes. Clin. Exp. Immunol. 52:551-560.

208. Hersey, P., Edwards, A., McCarthy, W.H. and Milton, G.W. (1982c) Tumour related changes and prognostic significance of natural killer cell activity in melanoma patients. In: “Natural Cell Mediate Immunity”, Vol. 2. Ed. Herberman, R.B., Acad. Press, N.Y., p. 1167-1174.

209. Hersey, P. (1982) Immunotherapy of leukaemia. In: “Leukaemia”. Eds. Gunz and Henderson, Grune and Stratton, p. 543-556.

210. Bindon, C., Hersey, P., Ruell, P., Edwards, A., McCarthy, W.H. and Harris, R. (1983) Clearance of systemically administered interleukin 2 (IL2) from the circulation of human subjects. Brit. J. Cancer 47:123-133.

40

211. Hersey, P., Bindon, C., Edwards, A., Murray, E., Phillips, G. and McCarthy, W.H. (1981) Induction of cytotoxic activity in human lymphocytes against autologous and allogeneic melanoma cells in vitro by culture with interleukin 2. Int. J. Cancer 28:695-703.

212. Hersey, P., Edwards, A., Lewis, R., Singh, S., Kemp, A. and McInnes, J. (1982) Deficient natural killer cell activity in a patient with Fanconi’s anaemia and squamous cell carcinoma. Association with defect in interferon release. Clin. Exp. Immunol. 48:205.

213. Hersey, P., Hobbs, A., Edwards, A., McCarthy, W.H. and McGovern, V.J. (1982) Analysis of the relation between natural killer cell activity and histologic features of lymphocyte infiltration and partial regression of the primary tumour in melanoma patients. Cancer Research 42(1):363-368.

214. Hersey, P. (1981) Developments in immune complex therapy and its application to cancer. In: “Human Cancer Immunology”. Eds. Serrou and Rosenfeld, North Holland, p. 135-166.

215. Ruell, P., Murray, E., McCarthy, W.H. and Hersey, P. (1982) Evaluation of assays to detect immune complexes as an immunodiagnostic aid in patients with melanoma. Oncodevelopmental Biology and Medicine 3:1-12.

216. Werkmeister, J., Phillips, G., McCarthy, W.H. and Hersey, P. (1981b) Suppressor cell activity in melanoma patients. II: Concanavalin-A induced suppressor cells inrelation to tumour growth and suppressor T cell subsets. Int. J. Cancer 28:11-15.

217. Werkmeister, J., McCarthy, W.H. and Hersey, P. (1981a) Suppressor cell activity in melanoma patients. I. Relation to tumour growth and immunoglobulin levels in vivo. Int. J. Cancer 28:1-9.

218. Hersey, P., Ho, K., Werkmeister, J. and Abele, U. (1981) Inhibition of suppressor T cells in pokeweed mitogen stimulated cultures of T and B cells by levamisole in vitro and in vivo. Clin. Exp. Immunol. 46:360.

219. Hersey, P. and McCarthy, W.H. (1982) The nature and significance of melanoma antigens recognized by human subjects. In “Melanoma Antigens and Antibodies”. Eds. Ferrone and Reisfeld, Plenum Press, New York, p. 187-209.

220. Zaunders, J., Werkmeister, J., McCarthy, W.H. and Hersey, P. (1981) Characterization of antigens recognized by natural killer cells in cell culture supernatants. Brit. J. Cancer 43:5.

221. Werkmeister, J., Edwards, A., McCarthy, W.H. and Hersey, P. (1980c) Prognostic significance of expression of antigens on melanoma cells. Cancer Immunol. Immunotherapy 9:233.

222. Hersey, P., Murray, E. and McCarthy, W.H. (1981) Monitoring tumour growth by detection of melanoma antigens in sera using leukocyte dependent antibody inhibition assays. Cancer Immunol. Immunotherapy 10:67.

223. Wekmeister, J., Zaunders, J., McCarthy, W.H. and Hersey, P. (1980b) Characterization of an inhibitor of cell division released in tumour cell cultures. Clin. Exp. Immunol. 41:487.

41

224. Pullen, S. and Hersey, P. (1981) Reactivity of antisera to antigens of C type viruses with leukocytes from patients with acute leukaemia. Pathology 13:289.

225. Hersey, P., Murray, E. and McCarthy, W.H. (1980a) Tumour related changes in natural killer cell activity in melanoma patients. Influence of stage of disease, tumour thickness and age of patient. Int. J. Cancer 25:187.

226. Werkmeister, J., Zbroja, R., McCarthy, W.H. and Hersey, P. (1980a) Release of factors inhibiting cell division from cultured tumour cells. Clin. Exp. Immunol. 40:168.

227. Fitzsimmons, K.B., Nicholls, M.D., Billson, F.A., Robertson, T.I. and Hersey, P. (1980) Fungal retinitis: A case of torulopsis glabrate infection treated with miconazole. Brit. J. Ophthal. 65:672.

228. Type 4 (Cell mediated) ibid. III, 1979. Allergic drug reactions.

229. Type 3 (Immune complex type) ibid. 75, 1979. Allergic reactions.

230. Basger, B., Eckert, G.M. and Hersey, P. (1979) Type 2 (Cytotoxic type) allergic drug reactions. Thrombocytopenia and haemolytic anaemia. Aust. J. Hosp. Pharmacy 9:51.

231. Hersey, P., Murray, E. and Edwards, A. (1979) Leukocyte-dependent antibody assays in melanoma patients. In: “Immunodiagnosis of Human Cancer”. Ed. Herberman. Elsevier, North Holland, p. 559.

232. Hersey, P., Murray, E., Werkmeister, J. and McCarthy, W.H. (1979c) Detection of a small molecular weight antigen on melanoma cells by a human antiserum in leukocyte-dependent antibody assays. Brit. J. Cancer 40:615.

233. Hersey, P., Edwards, A., Honeyman, M. and McCarthy, W.H. (1979b) Low natural killer cell activity in familial melanoma patients and their relatives. Brit. J. Cancer 40:113.

234. Whitsed, H., McCarthy, W.H. and Hersey, P. (1979) Nephelometric detection of circulating immune complexes using monoclonal rheumatoid factor. J. Immunol. Methods 29:311.

235. Ferson, M., Edwards, A.E., Lind, A., Milton, G.W. and Hersey, P. (1979) Low natural killer cell activity and immunoglobulin levels associated with smoking in human subjects. Int. J. Cancer 23:603.

236. Morris, T.C.M., Vincent, P.C., Sutherland, R. and Hersey, P. (1979) Inhibition of normal human granulopoiesis in vitro by non-B, non-T lymphocytes. Brit. J. Haematol. 45:451.

237. Basger, B., Eckert, G., Hersey, P., Mitchell, A.S., Raftos, J. and Richards, D. (1979) Quinidine hypersensitivity and lymphocyte transformation test. Med. J. Aust. 1:246.

238. Pullen, S. and Hersey, P. (1979) Demonstration of blood group-like antigens on the T lymphocytes of acute leukaemia patients. Clin. Exp. Immunol. 39:403-410.

239. Hersey, P. (1979) Natural killer cells – A new cytotoxic mechanism against tumours. Aust. N.Z. J. Med. 9:464.

240. Hersey, P., Edwards, A., Shaw, H. and Milton, G.W. (1979a) Relationship of natural killer cell activity to rhesus antigen in human subjects. Brit. J. Cancer 9:234.

42

241. Hersey, P., Isbister, J., Murray, E., Edwards, A., Milton, G.W. and Biggs, J. (1978) Removal of serum blocking factors against melanoma LDA by plasmapheresis. Aust. & N.Z. J. Surg. 48:26.

242. Murray, E., Ruygrok, S., Milton, G.W. and Hersey, P. (1978) Analysis of serum blocking activity against melanoma LDA. Int. J. Cancer 21:578.

243. Hersey, P., Edwards, A., Murray, E., McCarthy, W.H. and Milton, G.W. (1978) Sequential changes in leukocyte-dependent antibody activity in melanoma patients. Europ. J. Cancer 14:629.

244. Hersey, P., Edwards, A., Milton, G.W. and McCarthy, W.H. (1978) Relationship of cell-mediated cytotoxicity against melanoma cells to prognosis in melanoma patients. Brit. J. Cancer 37:505.

245. Morgan, G., McCarthy, W.H. and Hersey, P. (1977) Detection of carcino-embryonic-like antigen on melanoma cells by leukocyte-dependent antibody assays. Brit. J. Cancer 36:445.

246. Hersey, P. and McCarthy, W.H. (1977) Immunotherapy of solid tumours. Aust. N.Z. J. Surg. 47:701.

247. Hersey, P. (1977) Recent views on tumour antigens and their relationship to host defence mechanisms. Aust. N.Z. J. Med. 7:526.

248. Hersey, P. (1976) New approaches in immunotherapy (Comment). Med. J. Aust. 1:83.

249. Hersey, P., Morgan, G., Stone, D.E. and McCarthy, W.H. (1977) Previous pregnancy as a protective factor against death from melanoma. Lancet 1:451.

250. Murray, E., McCarthy, W.H. and Hersey, P. (1977) Blocking factors against leukocyte-dependent melanoma antibody in the sera of melanoma patients. Brit. J. Cancer 36:7.

251. Hersey, P., Honeyman, M., Edwards, A., Adams, E. and McCarthy, W.H. (1976) Antigens on melanoma cells detected by leukocyte-dependent antibody assays of human melanoma antisera. Int. J. Cancer 18:564.

252. Geddes-Dwyer, V., Hersey, P. and Cameron, D.A. (1977) Enhanced osteosarcoma growth produced in rats by osteosarcoma allografts. Brit. J. Cancer 35:86.

253. Johnston, P. and Hersey, P. (1976) Anti-leukaemia effect as a bystander effect of graft-versus-host reaction. Brit. J. Cancer 33:370.

254. Hersey, P., Edwards, A. and Edwards, J. (1976) Characterization of effector cells in human blood. Clin. Exp. Immunol. 23:140.

255. Hersey, P., Edwards, A., Adams, E., Isbister, J., Murray, E., Biggs, J. and Milton, G.W. (1976) Antibody-dependent, cell-mediated cytotoxicity against melanoma cells induced by plasmapheresis. Lancet 1:825.

256. Hersey, P., Edwards, A., Edwards, J., Adams, E., Milton, G.W. and Nelson, D.S. (1975b) Specificity of cell-mediated cytotoxicity against human melanoma lines. Evidence for “non-specific” killing by activated T cells. Int. J. Cancer 16:173.

257. Hersey, P., Edwards, J., Edwards, A., Adams, E., Kearney, R. and Milton, G.W. (1975a) Comparison of 51Cr release and microcytotoxicity assays against human melanoma cells. Int. J. Cancer 16:164.

43

258. Hersey, P. (1973) Macrophage effector function. Transplantation 15:282-290.

259. Hersey, P., Edwards, A.E., Edwards, J., Nelson, D.S. and Milton, G.W. (1976) Effector cells and specificity of cell-mediated cytotoxicity against human melanoma cell lines. In: “Pigment Cell” 2:191.

260. Walls, R.S., Hersey, P. and Quie, P.G. (1974) Macrophage eosinophil interactions in the inflammatory response to Trichinella Spiralis. Blood 44:131.

261. Campbell, A.C., Wiernik, G., Wood, J., Hersey, P., Waller, C.A. and MacLennan, I.C.M. (1976) Characteristics of lymphoma induced by radiotherapy. Clin. Exp. Immunol. 23:200.

262. II. The effects of azathioprine on lymphoid cell populations in a double-blind trial in ulcerative colitis. Clin. Exp. Immunol. 24:249.

263. Campbell, A.C., Skinner, J.M., Hersey, P., Roberts-Thompson, P., MacLennan, I.C.M. and Truelove, S.C. (1974, 1976) Immunosuppression in the treatment of bowel disease. I. Changes in the lymphoid populations in blood and rectal mucosa following cessation of treatment with azathioprine. Clin. Exp. Immunol. 16:521.

264. Campbell, A.C., Hersey, P., Harding, B., Hollingsworth, P.M., Skinner, J. and MacLennan, I.C.M. (1973) Effects of anti-cancer agents on immunological status. Brit. J. Cancer 29:254 (Suppl. I).

265. Campbell, A.C., Hersey, P., MacLennan, I.C.M., Kay, H.E.M., Pike, M.C. and the Medical Research Council’s Working Party on Leukaemia in Childhood (1973) Immunosuppressive consequences of radiotherapy and chemotherapy in patients with acute lymphoblastic leukaemia. Brit. Med. J. 2:395.

266. Hersey, P., Cullen, P. and MacLennan, I.C.M. (1973) Lymphocyte-dependent antibody against human transplantation antigen. Transplantation 16:9.

267. Hersey, P., MacLennan, I.C.M., Campbell, A.C., Harris, R. and Freeman, C.B. (1973) Cytotoxicity against human leukaemia cells. I. Demonstration of antibody dependent lymphocyte killing of human allogeneic myeloblasts. Clin. Exp. Immunol. 14:159.

268. Hersey, P. and MacLennan, I.C.M. (1973) Macrophage-dependent protection of tumour cells. Immunol. 24:385.

269. Hersey, P. (1973) The protective effect of antisera against leukaemia in vivo. A re-appraisal. Brit. J. Cancer 28:11 (suppl. I).

270. Hersey, P. (1973) Lymphocyte-dependent antibody. A new look at anti-serum therapy of leukaemia. Nature 244:22.

271. Hersey, P. (1973) Thymus-dependent cytotoxic lymphocytes in rat. Europ. J. Immunol.

272. Hersey, P. and MacLennan, I.C.M. (1972) Two unconventional mechanisms for immunological enhancement. Trans. Proc. 4:277.

273. Hersey, P. (1971) The separation and 51Cr labelling of human lymphocytes with in vivo studies of survival and migration. Blood 32:360.

Manuscripts under consideration for publication

44

Jin L, Hu WL, Jiang CC, Wang JX, Han CC, Zhang LJ, Thorne RF, Wilmott J, Scolyer R, Hersey P, Zhang XD.* Wu M. p53 regulation of Mcl-1 via microRNA-149* in melanoma.

45

INVITED REVIEWS IN REFEREED JOURNALS AND CHAPTERS IN BOOKS

1. Hersey, P. (1977) Recent views on tumour antigens and their relationship to host defence mechanisms. Aust. N.Z. J. Med. 7:526.

2. Hersey, P. (1979) Natural killer cells – A new cytotoxic mechanism against tumours. Aust. N.Z. J. Med. 9:464.

3. Hersey, P., Murray, E. and Edwards, A. (1979) Leukocyte-dependent antibody assays in melanoma patients. In: Immunodiagnosis of Human Cancer, Ed. Herberman, Elsevier North Holland, p.599.

4. Hersey, P. and McCarthy, W.H. (1982) The nature and significance of melanoma antigens recognized by human subjects. In: Melanoma Antigens and Antibodies, Eds. Ferrone and Reisfeld, Plenum Press, New York, p.187-209.

5. Hersey, P. (1981) Developments in immune complex therapy and its application to cancer. In: Human Cancer Immunology, Eds. Serrou and Rosenfeld, North Holland, p.135-166.

6. Hersey, P., Edwards, A., McCarthy, W.H. and Milton, G.W. (1982c) Tumour related changes and prognostic significance of natural killer cell activity in melanoma patients. In: Natural Cell Mediated Immunity, Vol. 2, Ed. Herberman, Acad. Press, New York, p.1167-1174.

7. Hersey, P. (1982) Immunotherapy of Leukaemia. In: Leukaemia, Eds. Gunz and Henderson, Grune and Stratton, p.543-556.

8. Balch, C. and Hersey, P. (1985) Current status of adjuvant therapy. In: Cutaneous Melanoma. Clinical Management and Treatment Results Worldwide, Eds. Balch and Milton, J.B. Lippincott Co., Philadelphia, p.197-218.

9. Hersey, P. (1985) Review of melanoma antigens recognized by monoclonal antibodies. Their functional significance and applications in diagnosis and treatment of melanoma. Pathology, 17:346-354.

10. Hersey, P. (1986) The evolving role of recombinant alpha interferons in the treatment of malignancies. Aust. & N.Z. J. Med., 16:425-437.

11. Hersey, P., MacDonald, M., Schibeci, S. and Burns, C. (1987) Clonal analysis of the nature and specificity of cytotoxic T cells in melanoma patients. In: Cutaneous Melanoma – Status of Knowledge and Future Perspective, Eds. U. Veronesi, N. Cascinelli and M. Santinami. Acad. Press, p.421-432.

12. Hersey, P. and Bolhuis, R.L.H. (1987) Factors influencing the generation of “non specific” MHC unrestricted cytotoxic T cells and receptors involved in their activity. Immunol. Today 8:233-239.

13. Hersey, P. (1989) “Natural immunity” mediated by activated cytotoxic T lymphocytes. In: Natural Immunity, Ed. Nelson, D.S. Acad. Press, p.123-146.

14. Hersey, P. (1989) Preclinical and phase I studies of monoclonal antibodies in melanoma. Application to Boron neutron capture therapy of melanoma. Pigment Cell Res., 2(4):264-272.

46

Continued… Invited Reviews in Refereed Journals and Chapters in Books

15. Hersey, P. (1989) Monoclonal antibodies as immunomodulating agents in the treatment of melanoma. In: Human Melanoma. Immunology, Diagnostics and Therapy, Ed. Ferrone, S. Springer Verlag, N.Y., p.387-396.

16. Hersey, P., Meldrum, C. and MacDonald, M. (1990) Identification of antigens recognized by T cells. In: Focus on Laboratory Methods in Immunology, Ed. Zola, H. CRC Press Inc., p.185-194.

17. Hersey, P. (1990) Current status of active specific immunotherapy of melanoma. In: Therapy of advanced malignant melanoma, Ed. Rumpke, P. S. Karger, AG Basel, p.183-200.

18. Hersey, P. (1989) Detection of immunity to human neoplasms. In: Current Opinions in Immunology, Vol. 1, No. 5, Cancer and Immunology. Ed. Moore, M., Current Science, Alden Press, Oxford, p.895-899.

19. Hersey, P. (1990) Biological agents in treatment of cancer. Aust. N.Z. J. Med., 20:85-98.

20. Hersey, P., Meldrum, C., Daniels, V., Werkman, H. and Sneddon, D. (1990) Characterization of melanoma antigens recognized by human T cells. In: Cellular Immunity and Immunotherapy of Cancer, UCLA Symposia on Molecular and Cellular Biology, New Series, Volume*. Ed. Lotze, M.T. and Finn, O.J. Wiley-Liss, Inc., New York, NY. P.343-349.

21. Hersey, P. and MacDonald, M. (1990) Fc receptors as mediators of MHC-unrestricted lysis by activated type 2 T cells. In: 6th Int. NK Workshop, Ed. Schmidt, R.E. S. Karger, AG Basel. P.94-98.

22. Hersey, P. (1991) Ganglioside antigens in tissue sections of skin, naevi and melanoma – implications for treatment of melanoma. In: Cancer Treatment and Research. Melanoma Research: Genetics, Growth Factors, Metastases, and Antigens. Ed. Nathanson, L. Kluwer Academic Publishers. P.137-151.

23. Hersey, P. (1991) Non-surgical treatment of melanoma. Australian Prescriber, 14:36-37.

24. Hersey, P. (1990) Immunotherapy of malignant melanoma. Cancer Forum, 14:24-31.

25. Hersey, P. (1992) Vaccinia viral lysates in treatment of melanoma. In: Biological Approaches to Cancer Treatment: Biomodulation. Ed. Mitchell, M.S. McGraw Hill, New York. P.302-325.

26. Hersey, P. (1992) Examination of the scientific basis for vaccines in treatment of melanoma. Vaccine Research 1:357-372.

27. Hersey, P. and Strong, T. (1992) Risk factors for presentation with thick primary melanoma include older age, male sex, smoking and may include occupation in certain industries. In: Epidemiologic Aspects of Melanoma. Ed. Gallagher, R.P., Kluwer Academic Publishers.

47

Continued… Invited Reviews in Refereed Journals and Chapters in Books

28. Hersey, P. (1992) Cytokines in melanoma therapy. Interferons and Cytokines, 21:6-11.

29. Hersey, P. (1993) The current status of immunotherapy for melanoma. Cancer Forum, July, 1993. 100-106.

30. Hersey, P. (1993) Cellular Therapy. Current Opinion in Oncology, 5:1049-1054.

31. Hersey, P. (1994) Melanoma Vaccines. Current Status and Future Prospects. Drugs, 47:373-382.

32. Hersey, P. (1997) Interferon in skin tumors. Melanoma and basal cell carcinoma. Clinical Applications of the Interferons. Eds. Penny, R. and Stuart-Harris, R. Chapman and Hall, London. P. 1699-183.

33. Hersey, P. (1996) Melanoma peptides in treatment of melanoma. Life Science, 8:34-38.

34. Hersey, P. (1997) Foreword to “Current Status of Melanoma Vaccines”. The Oncology Review. Issue 14.

35. Hersey, P. (1998) Impediments to Successful Immunotherapy. Pharmacology & Therapeutics 81:111-119.

36. Hersey, P. (1998) Cancer vaccines in therapy of cancer. Primer on Tumor Immunology. Eds. Parmiani, G. and Lotze, M. Harwood Academic Press.

37. Hersey, P. (2000) Will vaccines really work for melanoma? Melanoma: Critical Debates. Eds. Newton-Bishop and Gore. Blackwell Science (In press).

38. Curry, B.J., Myers, K. and Hersey, P. (2000) Utility of tests for circulating melanoma cells (CMCs), in identifying patients who develop recurrent melanoma. Recent Results in Cancer Research 158:211-230.

39. Hersey, P. and Zhang, X.D. (2001) How melanoma cells evade TRAIL induced apoptosis. Nature Reviews Cancer 1:142-150.

40. Hersey, P. (2002) Advances in non-surgical treatment of melanoma. Expert Opinion on Investigational Drugs 11:75-85.

41. Hersey, P. (2003) Adjuvant therapy for high risk primary and resected metastatic melanoma. Internal Medicine Journal 33:33-43.

42. Hersey, P. (2002) “Immunotherapy”. In: World Cancer Report. Eds: Stewart, B.W. IARC 210-214.

43. Hersey, P. (2004) Vaccinia viral lysates in immunotherapy of melanoma. In: Virus Therapy of Human Cancers. Eds: Sinkovics, J.G. and Horvath, J.C. Marcel Dekker, Inc. New York. Pages 691-712.

44. Hersey, P. and Zhang, X.D. (2003) Overcoming resistance of melanoma cells to apoptosis. Journal of Cellular Physiology 196:9-18.

45. Hersey, P. (2004) Immunotherapy of melanoma: principles. In: Textbook of Melanoma. Eds. Thompson, JF, Morton, DL, & Kroon, BBR. Martin Dunitz/Taylor and Francis. London. 54:559.

48

46. Hersey, P., Morton, D.L. and Eggermont, A. (2004) Adjuvant therapy for high-risk primary melanoma and resected metastatic melanoma. In: Textbook of Melanoma. Eds: Thompson, JF, Morton, DL, & Kroon BBR. Martin Dunitz/Taylor and Francis. London. 55:573.

47. Hersey, P. (2004) Immunotherapy of non-resected melanoma. In: Textbook of Melanoma. Eds. Thompson, JF, Morton, DL, & Kroon, BBR. Martin Dunitz/Taylor and Francis. London. 57:559.

48. Hersey, P., Zhang, X.Y. and Zhang, X.D. (2004) Regulation of TRAIL receptor expression in human melanoma. In: Death Receptors in Human Cancer. Eds: El-Deiry, W.S. Human Press. New Jersey, pages 175-187.

49. Zhang, X.D., Wu, J.J., Gillespie,S., Borrow, J. and Hersey, P. (2005) Cross resistance of melanoma to TRAIL induced apoptosis and chemotherapy. In: Cancer Chemotherapy & Biological Response Modifiers Annual.

50. Thompson, J.F., Shaw, H.M., Hersey, P. and Scolyer, R.A. (2004) The history and future of melanoma staging. Journal of Surgical Oncology 86(4):224-235.

51. Hersey, P. (2005) Immunotherapy of Melanoma – Past, Present and Future. In: Cancer Forum. The Cancer Council, Australia.

52. Hersey, P., Zhuang, L. and Zhang, X.D. (2006). Current strategies in overcoming resistance of cancer cells to apoptosis. Melanoma as a model. In: International Review of Cytology – A Survey of Cell Biology. Ed: Jeon, K.W. Elsevier, California. P131-158.

53. Hersey P., (2006) Apoptosis and Melanoma. How new insights are effecting the development of new therapies for melanoma. In current Opinion in Oncology 18:189-196. (IF: 4.544)

54. Hersey, P., Zhang, X.D. and Mhaidat, N. (2007). Overcoming resistance to apoptosis in cancer therapy. In: Programmed Cell Death in Cancer Progression and Therapy. Eds: Khosravi-Far, R. and White, E.

55. Hersey, P. and Zhang, X.D. (2008). Adaptation to ER stress as a driver of malignancy and resistance to therapy in human melanoma. Pigment Cell & Melanoma Research 21(3):358-367.

56. Kirkwood, J., Sondak, V., Hersey, P., and Gogas, H. (2008). Chapter 33: Adjuvant therapy for cutaneous melanoma. Fourth Edition. Eds: Balch, C.M. Lippincott, NY.

57. Hersey, P., Bastholt, L., Chiarion-Sileni, V., Cinat, G., Dummer, R., Eggermont, A.M.M., Espinosa, E., Haushchild, A., Quirt, I., Robert, C., and Schadendorf, D. (2009) Small molecules and targeted therapies in distant metastatic disease. Ann. Oncol. Aug;20 Suppl 6:vi35-40. (IF: 4.935)

58. Schadendorf, D., Algarra, S.M., Bastholt, L., Cinat, G., Dreno, B., Eggermont, A.M.M., Espinosa, E., Guo, J., Hauschild, A., Petrella, T., Schachter, J., and Hersey, P. (2009). Immunotherapy of distant metastatic disease. Ann. Oncol. Aug;20 Suppl 6:vi41-50. (IF: 4.935)

49

59. Gogas, H., Eggermont, A.M.M., Haushchild, A., Hersey, P., Mohr, P., Schadendorf, D., Spatz, A., and Dummer, R. (2009). Biomarkers in Melanoma. Ann. Oncol. Aug;20 Suppl 6:vi8-13. (IF: 4.935)

60. Eggermont, A.M.M., Testori, A., Marsden, J., Hersey, P., Quirt, I., Petrella, T., Gogas, H., MacKie, R.M., and Hauschild, A. (2009). Utility of adjuvant systemic therapy in melanoma. Ann. Oncol. Aug;20 Suppl 6:vi30-34. (IF: 4.935)

61. Hersey, P., Watts, R.N., Zhang, X.D., and Hackett, J. (2009) Metabolic approaches to treatment of melanoma. Clinical Cancer Research 15:6490-6494.

62. Hersey, P. and Zhang, X.D. (2009) Treatment combinations targeting apoptosis to improve immunotherapy of melanoma. Cancer Immunology Immunotherapy 58(11):1751-1761.

63. Hersey, P. and Zhang, X.D. (2010) Targeting apoptotic pathways in melanoma. In: Targeted Therapeutics in Melanoma. Editors Gajewski T and Hodi S, Humana Press 2010 (in press)

50